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A B S T R A C T
Background
Tuberculous pericarditis can impair the heart’s function and cause death; long term, it can cause the membrane to fibrose and constrict
causing heart failure. In addition to antituberculous chemotherapy, treatments include corticosteroids, drainage, and surgery.
Objectives
To assess the effects of treatments for tuberculous pericarditis.
Search methods
We searched theCochrane InfectiousDiseasesGroupSpecializedRegister (27March 2017); theCochraneCentral Register ofControlled
Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27
March 2017); and LILACS (1982 to 27 March 2017). In addition we searched the metaRegister of Controlled Trials (mRCT) and
the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal using ’tuberculosis’ and
’pericard*’ as search terms on 27 March 2017. We searched ClinicalTrials.gov and contacted researchers in the field of tuberculous
pericarditis. This is a new version of the original 2002 review.
Selection criteria
We included randomized controlled trials (RCTs) and quasi-RCTs.
Data collection and analysis
Two review authors independently screened search outputs, evaluated study eligibility, assessed risk of bias, and extracted data; and we
resolved any discrepancies by discussion and consensus. One trial assessed the effects of both corticosteroid and Mycobacterium indicus
pranii treatment in a two-by-two factorial design; we excluded data from the group that received both interventions. We conducted
fixed-effect meta-analysis and assessed the certainty of the evidence using the GRADE approach.
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Main results
Seven trials met the inclusion criteria; all were from sub-Saharan Africa and included 1959 participants, with 1051/1959 (54%) HIV-
positive. All trials evaluated corticosteroids and one each evaluated colchicine, M. indicus pranii immunotherapy, and open surgical
drainage. Four trials (1841 participants) were at low risk of bias, and three trials (118 participants) were at high risk of bias.
In people who are not infected with HIV, corticosteroids may reduce deaths from all causes (risk ratio (RR) 0.80, 95% confidence
interval (CI) 0.59 to 1.09; 660 participants, 4 trials, low certainty evidence) and the need for repeat pericardiocentesis (RR 0.85, 95%
CI 0.70 to 1.04; 492 participants, 2 trials, low certainty evidence). Corticosteroids probably reduce deaths from pericarditis (RR 0.39,
95% CI 0.19 to 0.80; 660 participants, 4 trials, moderate certainty evidence). However, we do not know whether or not corticosteroids
have an effect on constriction or cancer among HIV-negative people (very low certainty evidence).
In people living with HIV, only 19.9% (203/1959) were on antiretroviral drugs. Corticosteroids may reduce constriction (RR 0.55,
0.26 to 1.16; 575 participants, 3 trials, low certainty evidence). It is uncertain whether corticosteroids have an effect on all-cause death or
cancer (very low certainty evidence); and may have little or no effect on repeat pericardiocentesis (RR 1.02, 0.89 to 1.18; 517 participants,
2 trials, low certainty evidence).
For colchicine among people living with HIV, we found one small trial (33 participants) which had insufficient data to make any
conclusions about any effects on death or constrictive pericarditis.
Irrespective of HIV status, due to very low certainty evidence from one trial, it is uncertain whether adding M. indicus pranii im-
munotherapy to antituberculous drugs has an effect on any outcome.
Open surgical drainage for effusion may reduce repeat pericardiocentesis In HIV-negative people (RR 0.23, 95% CI 0.07 to 0.76; 122
participants, 1 trial, low certainty evidence) but may make little or no difference to other outcomes. We did not find an eligible trial that
assessed the effects of open surgical drainage in people living with HIV.
The review authors found no eligible trials that examined the length of antituberculous treatment needed nor the effects of other
adjunctive treatments for tuberculous pericarditis.
Authors’ conclusions
For HIV-negative patients, corticosteroids may reduce death. For HIV-positive patients not on antiretroviral drugs, corticosteroids
may reduce constriction. For HIV-positive patients with good antiretroviral drug viral suppression, clinicians may consider the results
from HIV-negative patients more relevant.
Further research may help evaluate percutaneous drainage of the pericardium under local anaesthesia, the timing of pericardiectomy in
tuberculous constrictive pericarditis, and new antibiotic regimens.
P L A I N L A N G U A G E S U M M A R Y
Treatment for tuberculosis infection of the membrane around the heart
What is the issue?
Tuberculosis infection of the pericardium surrounding the heart is uncommon but life-threatening.
What is the aim of this review?
The aim of this Cochrane Review was to assess the effects of treatments for people with tuberculous pericarditis.
What is this important?
Doctors prescribe antituberculous drugs for six months, drain fluid from the pericardium if the patient has heart failure, and sometimes
remove the pericardium if it is thick and making the patient ill and sometimes give corticosteroids to reduce the effects of the
inflammation.
What are the main results of the review?
Cochrane researchers collected and examined all potentially relevant studies and found seven trials, all conducted in sub-Saharan Africa.
Six trials evaluated corticosteroids. Other treatments evaluated includedMycobacterium indicus pranii immunotherapy, colchicine, and
surgical removal of fluid under general anaesthesia. This review is a new edition of the 2002 review.
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In people not infected with HIV, six trials found that additional steroids may reduce deaths overall (low certainty evidence) and probably
reduce deaths caused by pericarditis (moderate certainty evidence). Steroids may prevent reaccumulation of fluid in the pericardial space
(low certainty evidence). However, we do not know whether or not corticosteroids have an effect on constriction or cancer among HIV-
negative people (very low certainty evidence).
In people livingwithHIV,most people evaluated in the included trials were not on antiretroviral drugs. For these patients, corticosteroids
may reduce constrictive pericarditis (low certainty evidence), but we do not know if this translates into a reduction in the number of
deaths or cancer (very low certainty evidence). Corticosteroids may have little or no effect on reaccumulation of fluid in the pericardial
space (low certainty evidence).
Colchicine was evaluated in one trial of 33 people, with insufficient data to make any conclusions about an effect.
Based on one trial, it is uncertain whether adding M. indicus pranii immunotherapy to antituberculous drugs has an effect on any
outcome in people with tuberculous pericarditis regardless of their HIV status (very low certainty evidence).
Open surgical drainage of the fluid accumulating between the heart and the membrane using general anaesthesia may be associated
with less life-threatening reaccumulation of fluid in people who are not infected with HIV, but conclusions are not possible as the
number of participants studied was too small. We did not find an eligible trial that assessed the effects of open surgical drainage in
people living with HIV.
The review authors found no eligible trials that examined the length of antituberculous treatment needed nor the effects of other
adjunctive treatments for tuberculous pericarditis.
How up-to-date is this review?
The review authors searched for trials published up to 27 March 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Population: HIV-negat ive people with tuberculous pericardit is
Settings: any sett ing
Intervention: cort icosteroids
Comaprison: placebo
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Placebo Steroids
Death f rom all causes 22 per 100 18 per 100
(13 to 24)
RR 0.80
(0.59 to 1.09)
660
(4 trials)
⊕⊕©©
low1,2
Steroids may reduce the
risk of deaths f rom all
causes among HIV-neg-
at ive people
Death f rom pericardit is 8 per 100 3 per 100
(1 to 6)
RR 0.39
(0.19 to 0.80)
660
(4 trials)
⊕⊕⊕©
moderate2
Steroids probably re-
duce the risk of deaths
f rom pericardit is among
HIV-negat ive people
Constrict ive pericardi-
t is
10 per 100 7 per 100
(3 to 15)
RR 0.72
(0.34 to 1.55)
281
(2 trials)
⊕©©©
very low2,3,4
It is uncertain whether
steroids have an ef fect
on the risk of constric-
t ion among HIV-nega-
t ive people
Repeat pericardiocen-
tesis
40 per 100 34 per 100
(28 to 41)
RR 0.85
(0.70 to 1.04)
492
(2 trials)
⊕⊕©©
low1,4
Steroids may reduce
the risk of repeat
drainage of the peri-
cardium among HIV-
negat ive people
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Cancer 1 per 100 1 per 100
(0 to 12)
RR 0.85
(0.05 to 13.80)
256
(1 trial)
⊕©©©
very low3,5
It is uncertain whether
steroids have an ef -
fect on the risk of can-
cer among HIV-negat ive
people
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1We downgraded by 1 for imprecision: the CI ranges f rom a large clinical benef it to a small increase in harm.
2We downgraded by 1 for study lim itat ions: one trial was at high risk of bias.
3We downgraded by 2 for imprecision: the CI ranges f rom clinically important benef its to a large increase in harm.
4We downgraded by 1 for select ive report ing: data were only reported by 2 of the 4 trials that recruited HIV-negat ive people.
5We downgraded by 1 for select ive report ing: data were only reported by 1 of the 4 trials that recruited HIV-negat ive people.
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B A C K G R O U N D
Description of the condition
Tuberculous pericarditis refers to an infection of the membrane
that covers the heart (pericardium) by the bacterium Mycobac-
terium tuberculosis. Infection of the pericardium can result in
fluid accumulation around the heart, which constrains the heart’s
pumping action (tamponade), and is life-threatening. Sometimes
the infection causes a thickening of the pericardium without an
effusion (constrictive pericarditis), and this can also constrain the
pumping action (Mayosi 2005; Ntsekhe 2012). Tuberculous peri-
carditis manifests with fatigue, shortness of breath, swelling of the
body, and can cause death.
Healthcare practitioners in low- and middle-income countries,
where tuberculosis is common, are familiar with the condition
(Gelfand 1957; Strang 1984). In high-income countries, the con-
dition occurs in less than 5% of all people with tuberculosis
(Lorell 1997; Imazio 2015). The human immunodeficiency virus
(HIV) epidemic has resulted inmore cases of tuberculosis in Africa
and other resource-constrained regions, with a consequent rise in
tuberculous pericarditis (Cegielski 1990; Mayosi 2006; Mayosi
2008). Post-mortem examinations conducted before the HIV era
indicate that the pericardium is involved in 1% of people infected
with tuberculosis (Fowler 1991). However, identical studies in
people who died with advanced HIV reveal that extrapulmonary
disease with multiple organ involvement is more frequent (Lucas
1993; Rana 1997). In people living with HIV who have pericar-
dial effusion, tuberculosis is the cause in over four-fifths of cases
(Ntsekhe 2005). In addition, the burden of tuberculous pericardi-
tis experienced a rapid increase in regions of the worldwhere tuber-
culosis-HIV co-infection is common (Ntsekhe 2013). This could
be explained in part by the fact that the lifetime risk of tuberculo-
sis in immune-competent people without HIV infection is 10%
(Lawn 2011), which increases to a yearly risk of 10% early in HIV
infection and up to a 30% yearly risk in people with advanced
immunosuppression (Maartens 2007).
In the pre-antibiotic era, mortality of people with tuberculous
pericarditis was 80% to 90% (Harvey 1937), but the advent of
effective antituberculous chemotherapy in the 1940s resulted in a
decrease in case fatality rate to about 35%by 1970 (Rooney 1970).
However, even with antituberculous drug regimens that contain
rifampicin and isoniazid, the mortality rate remains high and is
estimated to be between 8% and 17% in people without HIV in-
fection (Desai 1979; Bhan 1980). In addition, HIV infection has
an adverse effect on mortality rate (Mayosi 2005; Ntsekhe 2008;
Wiysonge 2008). In one study, 185 participants with tuberculous
pericarditis were consecutively enrolled in 15 referral hospitals in
three African countries (Cameroon, Nigeria, and South Africa)
between March 2004 and October 2004; and followed up dur-
ing the six-month course of antituberculous treatment (Mayosi
2006). The mortality rate in this study was 17% in people with-
out clinical evidence of HIV infection and 40% in people with
clinical features of HIV infection (Mayosi 2008). HIV-associated
tuberculous pericarditis more often occurs as part of a dissemi-
nated process with a greater amount of heart muscle involvement,
and patients have larger fluid accumulation in the pericardium
(Ntsekhe 2013).
Description of the intervention
Doctors currently prescribe rifampicin, isoniazid, pyrazinamide,
and ethambutol for sixmonths; remove fluid from the pericardium
if the patient is very sick; and remove the membrane if it is thick
and making the patient ill (Mayosi 2002). However, the num-
ber of complications and deaths due to the disease remain high
(Mayosi 2008; Ntsekhe 2013). It has been proposed that adding
corticosteroids to antituberculous antibiotics would lead to fur-
ther decreases in the aggressiveness of the disease and deaths. Some
study authors recommend the routine use of corticosteroids in all
cases of tuberculous pericarditis (Alzeer 1993; Senderovitz 1994;
Strang 1997). In contrast, other experts advise that corticosteroids
should be reserved for people who are critically ill with recurrent
large effusion and who do not respond to pericardial drainage and
antituberculous drugs alone (Lorell 1997).
In addition to the corticosteroid controversy, there is no consen-
sus regarding the optimal use of other therapeutic interventions
(Ntsekhe 2013). Removal of fluid can be percutaneous under lo-
cal anaesthesia or surgical under general anaesthesia. Furthermore,
doctors can differ in the way they manage this condition in terms
of duration of antituberculous drugs and when to operate. Other
potential treatments for tuberculous pericarditis may include in-
trapericardial fibrinolysis (Augustin 2011), cellular therapy, use
of repurposed drugs, cytokine therapy (Zumla 2015), and surgi-
cal removal of the thickened membrane (that is pericardiectomy)
(Schrire 1967; Quayle 1987).
How the intervention might work
Length of treatment
Various specialists recommend different antibiotic treatment reg-
imens of different lengths, from six months to 12 months
(Sagristà-Sauleda 1988; Fowler 1991; Koh 1994; Strang 2004a;
Strang 2004b). It is uncertain whether longer treatment leads to
better outcomes (Mayosi 2002).
Corticosteroids
The inflammatory response to tuberculous bacilli penetrating the
pericardium is responsible for the morbidity and mortality associ-
ated with tuberculous pericarditis (Mayosi 2005). Corticosteroids
are anti-inflammatory drugs that may attenuate the inflammatory
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response and improve outcomes by reducing the accumulation of
fluid or development of adhesions in the pericardium (Wiysonge
2008). In people living with HIV, active tuberculosis increases im-
mune activation and accelerates progression to the acquired im-
munodeficiency syndrome; which results in early death. Corticos-
teroids may improve survival in HIV-positive people that have tu-
berculous pericarditis by modulating this immunological response
(Wiysonge 2008). However, there is concern that corticosteroids
may increase the risk of opportunistic infections and cancer in
people living with HIV (Mayosi 2014).
Immunomodulators
As a result of advancements in the understanding of the im-
munopathogenesis of tuberculosis, there has been an increasing
interest in immunotherapies as adjunctive treatments to stan-
dard antituberculous drug regimens.Mycobacterium indicus pranii
is a non-pathogenic, saprophytic, rapidly growing atypical My-
cobacterium species that has immunomodulating properties (Saini
2009). When administered as an intradermal heat-killed vaccine,
M. indicus pranii stimulates a Th1 cellular immune response
against shared epitopes for M. tuberculosis, which leads to an im-
proved cell-mediated immune response, and therefore less severe
disease (Ganju 1990; Singh 1992). A systematic review suggested
thatM. indicus pranii administration may reduce the time to cure
of pulmonary tuberculosis, while acknowledging the need for fur-
ther large trials (Pandie 2014).
Surgical options
Early drainage
Complete drainage of the pericardial fluid is sometimes performed
as an open surgical procedure under general anaesthesia (Strang
2004b), or percutaneously under local anaesthesia with ultrasound
or fluoroscopic guidance. The requirement and optimal method
for drainage is not known (Strang 2004b).
Removal of the pericardium
In tuberculous constrictive pericarditis, some specialists advise an
early conservative approach with surgery applied to patients who
do not respond after an initial period of antituberculous medi-
cation (Schrire 1967). Others advise early surgery in all affected
cases (Quayle 1987).
Why it is important to do this review
This is an update of a Cochrane Review first published in 2000
(Mayosi 2000), and previously updated in 2002 (Mayosi 2002).
The previous version included four trials of corticosteroids (Schrire
1959; Hakim 2000; Strang 2004a; Strang 2004b). Early publica-
tions of small trials conducted in the pre-HIV era reported fewer
deaths with corticosteroids compared to placebo, but the confi-
dence interval (CI) ranged from a substantial reduction to a clin-
ically important increase in deaths (risk ratio 0.65, 95% CI 0.36
to 1.16; 350 participants, 2 trials) (Strang 2004a; Strang 2004b).
Similar results were obtained among people living with HIV (risk
ratio 0.50, 95% CI 0.19 to 1.28; 58 participants, 1 trial) (Hakim
2000). One trial showed that complete drainage of the pericar-
dial fluid may relieve cardiac tamponade (Strang 2004b). How-
ever, two previously included trials have reported additional data
(Strang 2004a; Strang 2004b), and various potentially eligible tri-
als have been published since 2002 (Strang 2004a; Strang 2004b;
Cui 2005; Reuter 2006; Mayosi 2014; Liebenberg 2016).
O B J E C T I V E S
To assess the effects of treatments for tuberculous pericarditis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and quasi-RCTs.
Types of participants
People of all ages that required treatment for clinically diagnosed
tuberculous pericarditis (effusive, constrictive, or effusive-constric-
tive), whether HIV-negative or HIV-positive.
Types of interventions
• Long versus shorter durations of antituberculous
chemotherapy.
• Corticosteroids versus no corticosteroids.
• Immunomodulators versus no immunomodulators.
• Surgical procedures versus conservative management.
• Other treatments for tuberculous pericarditis.
Types of outcome measures
Primary outcomes
• Deaths from all causes.
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Secondary outcomes
• Death from pericarditis.
• Constrictive pericarditis.
• Repeat pericardiocentesis.
• Cancer.
• Hospitalization.
• Pericardiectomy.
• Opportunistic infections.
Search methods for identification of studies
Electronic searches
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
We searched the following databases using the strategy described
in Appendix 1: the Cochrane Infectious Diseases Group Special-
ized Register (27 March 2017); the Cochrane Central Register of
Controlled Trials (CENTRAL), published in the Cochrane Li-
brary (2017, Issue 2); MEDLINE (1966 to 27March 2017); Em-
base (1974 to 27 March 2017); and LILACS (1982 to 27 March
2017).
Searching other resources
We searched the metaRegister of Controlled Trials (mRCT) and
theWHOInternationalClinical TrialsRegistry Platform (ICTRP)
search portal using ’tuberculosis’ and ’pericard*’ as search terms
on 27 March 2017.
We also searched ClinicalTrials.gov and contacted researchers in
the field of tuberculous pericarditis in March 2017.
In addition, we examined existing reviews of tuberculous peri-
carditis for relevant citations (Schrire 1967; Bhan 1980; Fowler
1991; Fowler 1992; Alzeer 1993; Senderovitz 1994; Fowler 1995;
Cisneros 1996;Dooley 1997; Strang 1997;Mayosi 2002; Ntsekhe
2003; Mayosi 2005; Syed 2007; Imazio 2015; Zumla 2015).
Data collection and analysis
We conducted screening of search outputs, assessment of poten-
tially eligible studies, assessment of risk of bias, and data extrac-
tion for this review in line with the Cochrane policy on trial au-
thors who are also review authors (Kliner 2014). In addition, two
Cochrane Infectious Disease Group (CIDG) Editors (Paul Gar-
ner and David Sinclair) provided oversight for data collection and
analysis.
Selection of studies
Three review authors, Charles Wiysonge (CSW), Dumo Ma-
jombozi (DM), and Bongani M Mayosi (BMM), independently
screened abstracts identified by the search strategy for potentially
eligible studies. The three review authors obtained the full-text
articles of any potentially relevant articles and then assessed these
studies using the prespecified trial inclusion criteria, respecting
the Cochrane policy on trial authors who are also review authors
(Kliner 2014). We resolved any disagreements by discussion and
consensus.
Six review authors, Mpiko Ntsekhe (MN), Lehana Thabane (LT),
Jimmy Volmink (JV), Freedom Gumedze (FG), Shaheen Pandie
(SP), and BMM, were involved in one trial that met the inclusion
criteria of this review (Mayosi 2014). Two review authorswhowere
not involved with this trial, namely CSW and DM, independently
performed the application of the inclusion criteria, ’Risk of bias’
assessments, and data extraction for this trial. We excluded one
potentially eligible study that did not meet the inclusion criteria
and documented the reason for exclusion in the ’Characteristics
of excluded studies’ table. Four review authors, CSW, MN, FG,
JV, and BMM, are the authors of an excluded study (Wiysonge
2008). In order to conform to existing Cochrane policies (Higgins
2011; Kliner 2014), a review author who was not involved in this
study (DM) made the initial assessment of the eligibility of this
study. We have included a study that is awaiting assessment in the
’Characteristics of studies awaiting classification’ table (Cui 2005).
Data extraction and management
Two review authors (either CSW and BMM, or CSW and DM)
independently extracted information from the included trials on
methods used, participant characteristics, interventions, and out-
comes. For all outcomes, we extracted the number of participants
randomized and the number of participants analysed. The trials
identified and included in this review all randomized individual
participants and reported dichotomous outcomes. For each trial,
we extracted the number of participants randomized to each in-
tervention, as well as the number of participants with an outcome
of interest and the number included in the analysis by the trial
authors.
The published article from the Mayosi 2014 trial did not provide
data byHIV status, but we requested and obtained these data from
the study statistician (FG). CSW entered the data into Review
Manager (RevMan) (RevMan 2014), and the study statistician FG
verified the entered data for accuracy.
Multiple publications from the same data constituted one included
trial, andwemarked the publication that provided themost data to
the analyses as the primary reference (Hakim 2000; Strang 2004a;
Strang 2004b;Mayosi 2014). If data were available on prespecified
outcomes at two or more periods, we took the more complete or
later one into account (Strang 2004a; Strang 2004b).
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Assessment of risk of bias in included studies
One review author (CSW) assessed the risk of bias in each included
trial usingCochrane’s ’Risk of bias’ assessment tool for assessing the
risk of bias in intervention studies (Higgins 2011), and two review
authors (BMM and DM) verified this assessment; in line with
the Cochrane policy on trial authors who are also review authors
(Kliner 2014). We assessed whether adequate steps were taken
to reduce the risk of bias across seven specific domains, namely,
random sequence generation; allocation concealment; blinding
of participants and personnel; blinding of outcome assessment;
completeness of outcome data; selective outcome reporting; and
other issues. For each included trial, we described what the trial
authors reported that they did for each domain and decided the
risk of bias for that domain by assigning a judgement of ’low’,
’high’, or ’unclear risk’ of bias.
We categorized each included study into one of two levels of bias:
low or high risk of bias. Studies with a high risk of selection bias
(from inadequate random sequence generation and/or allocation
concealment), detection bias (from lack of blinding of outcome
assessment), or attrition bias (from incomplete outcome data) were
categorized as having high risk of bias. We considered all other
included trials to have a low risk of bias.We compared the results of
independent ’Risk of bias’ assessments and resolved disagreements
by consensus.
Measures of treatment effect
All of the included trials reported dichotomous data, so we ex-
pressed the results as risk ratios (RR) with 95% CIs for each out-
come.
Unit of analysis issues
We did not encounter any unit of analysis issues in this review, as
all included trials were individually RCTs.
Dealing with missing data
We stratified analyses by HIV status. However, data on HIV sta-
tus were unavailable in three trials that were conducted (or started
recruitment) in South Africa before the onset of the HIV epi-
demic in the country. We have assumed that the participants in
these studies did not have HIV infection (Schrire 1959; Strang
2004a; Strang 2004b). One trial only enrolled HIV-positive peo-
ple (Hakim2000), and two recruited bothHIV-positive andHIV-
negative people (Reuter 2006; Mayosi 2014). The published pa-
per from one of the two trials did not disaggregate results by HIV
status (Mayosi 2014). We requested and obtained the disaggre-
gated outcome data from the trial statistician (FG).
Assessment of heterogeneity
We assessed whether there was heterogeneity of study participants,
interventions, and outcomes in order to make a qualitative assess-
ment of the extent to which the included studies were similar to
each other. We then included clinically homogeneous studies in
meta-analyses and assessed heterogeneity of study results by visu-
ally inspecting the forest plots to check for overlapping CIs. In
addition, we assessed heterogeneity of effects using the Chi² test
of homogeneity; with statistical significance defined at the 10%
alpha level (that is, P = 0.10). We also used the I² statistic to quan-
tify the proportion of observed variation of effects across studies,
which reflected variation in true effect sizes rather than sampling
error (Higgins 2011).
Assessment of reporting biases
There were too few included studies to examine publication bias
using a funnel plot (Higgins 2011).
Data synthesis
Using both unpublished (Mayosi 2014), and published data
(Schrire 1959; Hakim 2000; Strang 2004a; Strang 2004b; Reuter
2006; Mayosi 2014), we analysed trial participants in groups to
which they were randomized; regardless of how much of the in-
tended intervention they actually received. One included study
used a 2 x 2 factorial design, in which participants received pred-
nisolone plusM. indicus pranii, prednisolone plus placebo,M. in-
dicus pranii plus placebo, or double placebo. There was a sugges-
tion of clinical interaction between prednisolone and M. indicus
pranii on cancer incidence (Mayosi 2014). Ten of the 14 cases
of cancer (71.4%) occurred in the group that took prednisolone
plus M. indicus pranii. Therefore, in the analysis of intervention
effects, we considered data from the group that took only one ac-
tive intervention (that is, prednisolone orM. indicus pranii, as the
case may be); and excluded data from the group that received both
interventions.
We used meta-analysis with a fixed-effect model to calculate the
summary statistics. We stratified analyses according to HIV status
and the type of treatment and control intervention, for example,
adjunctive corticosteroids versus placebo or no treatment in HIV-
negative people, adjunctive corticosteroids versus placebo or no
treatment in people living with HIV.
In addition, we used the GRADE (Grading of Recommendations
Assessment, Development and Evaluation) approach to assess the
certainty of the evidence for each outcome (Guyatt 2008).Wehave
summarized the certainty of the evidence for corticosteroids in the
’Summary of findings’ tables (Summary of findings for the main
comparison; Summary of findings 2), which we constructed using
GRADEpro Guideline Development Tool software (GRADEpro
GDT 2014).
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Subgroup analysis and investigation of heterogeneity
We only conducted meta-analyses for studies with homogeneous
participants, interventions, and outcomes. If we had at least 10
studies in any meta-analysis that showed significant statistical het-
erogeneity (that is, P < 0.10), we would have explored possible
sources of heterogeneity by performing subgroup analyses; with
subgroups defined by clinical syndromes of tuberculous pericardi-
tis (that is, pericardial effusion versus constriction) and risk of bias
(that is, low versus high).
R E S U L T S
Description of studies
Results of the search
We have presented a PRISMA diagram that illustrates the study
selection process in Figure 1.
Figure 1. Study flow diagram
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For this Cochrane Review update, we performed a literature search
up to 27 March 2017 covering all years; including the years cov-
ered by the previous version of the review (Mayosi 2002). This lit-
erature search yielded 17 publications. We judged four of the pub-
lications to be clearly irrelevant to the review and excluded them.
We obtained the full-text articles of the 13 potentially eligible pub-
lications and assessed them for eligibility. Four articles, which con-
tain data from four distinct studies (Schrire 1959; Hakim 2000;
Strang 2004a; Strang 2004b), were already included in the previ-
ous published version of the review (Mayosi 2002). We excluded
one article due to ineligible study design (Wiysonge 2008), and
another one is awaiting assessment (Cui 2005). One study has
not yet published outcome data and we classified it as ongoing
(NCT02673879). The remaining six publications, which contain
data from six distinct studies, met our inclusion criteria (Hakim
2000; Strang 2004a; Strang 2004b; Reuter 2006; Mayosi 2014;
Liebenberg 2016). The most recent follow-up data for two in-
cluded trials were published as one article (Strang 2004a; Strang
2004b).
Included studies
The seven eligible trials consisted of six single-country studies con-
ducted in SouthAfrica (Schrire 1959; Strang 2004a; Strang 2004b;
Reuter 2006; Liebenberg 2016) and Zimbabwe (Hakim 2000),
as well as a multicountry study conducted in Kenya, Malawi,
Mozambique, Nigeria, Sierra Leone, South Africa, Uganda, and
Zimbabwe (Mayosi 2014). The interventions evaluated were as
follows.
• Corticosteroids (Schrire 1959; Hakim 2000; Strang 2004a;
Strang 2004b; Reuter 2006; Mayosi 2014).
• Colchicine (Liebenberg 2016).
• M. indicus pranii immunotherapy (Mayosi 2014).
• Open surgical drainage on admission in participants with
tuberculous pericardial effusion (Strang 2004b).
We have provided details of the included studies in the ’
Characteristics of included studies’ tables.
Optimum duration of treatment
We did not find any eligible studies that assessed different dura-
tions of antituberculosis drug regimens .
Corticosteroids
We have provided key characteristics of the six included corticos-
teroid trials in Table 1.
The six trials enrolled a total of 1926 participants. Over half of the
participants (1018/1926; 52.9%) were confirmed HIV-positive.
Only one study gave antiretroviral drugs to participants, with 203
(22%) of these HIV-positive participants on antiretroviral drugs,
and thus overall only 19.9% of participants in the meta-analysis
on antiretroviral therapy at enrolment. Five trials enrolled peo-
ple with pericardial effusion (Schrire 1959; Hakim 2000; Strang
2004b; Reuter 2006; Mayosi 2014), and one enrolled those with
pericardial constriction (Strang 2004a).
The corticosteroids assessed were cortisone (Schrire 1959), pred-
nisone and triamcinolone hexacetonide (Reuter 2006), and pred-
nisolone (Schrire 1959;Hakim2000; Strang2004a; Strang2004b;
Mayosi 2014). Schrire 1959 did not specify the length of follow-
up and Reuter 2006 reported it as one year; Hakim 2000 as 18
months; Mayosi 2014 as two years; and Strang 2004a and Strang
2004b as 10 years.
Colchicine
One trial tested the effects of colchicine among 33 people with a
definite or probable diagnosis of tuberculous pericarditis in Kim-
berley, South Africa (Liebenberg 2016). All 33 participants were
HIV-positive and had pericardial effusion at enrolment. Partici-
pants in the intervention arm received colchicine 1.0 mg per day
for six weeks. The control arm received identical placebo for six
weeks as well. The length of follow-up was 16 weeks (Liebenberg
2016).
M. indicus pranii immunotherapy
One trial evaluated the effects of an immunomodulator,M. indicus
pranii, among 1250 people aged 18 years or older in sub-Saharan
Africa (Mayosi 2014). Two thirds (840/1250; 67.2%) of the par-
ticipants were confirmed to be HIV-positive; with 172 (20.5%)
on antiretroviral therapy at enrolment. All participants had peri-
cardial effusion at enrolment. The M. indicus pranii preparation
was given in five doses; at the time of enrolment and at 2 weeks, 4
weeks, 6 weeks, and 3 months. The control arm received identical
placebo following the same schedule, and the length of follow-up
was two years. This trial also assessed the effects of corticosteroids
(Mayosi 2014).
Surgical drainage
One trial assessed the effects of routine open surgical drainage
on admission compared to no open surgical drainage in 122 par-
ticipants with tuberculous pericardial effusion in Umtata, South
Africa (Strang 2004b). This trial was conducted before the onset
of the HIV epidemic in the country. This study reported data at
two years and at 10 years of follow-up. This trial also assessed the
effects of corticosteroids (Strang 2004b).
Intrapericardial fibrinolysis
We found an ongoing trial that is assessing the effects of complete
percutaneous pericardial drainage using intrapericardial alteplase
compared to conventional pericardiocentesis inCapeTown, South
Africa. The study started in 2016 and plans to recruit 2176 peo-
ple with large pericardial effusion due to tuberculous and non-tu-
berculous pericarditis. The trial started with a pilot phase involv-
ing 218 people. This will confirm the feasibility of conducting a
11Interventions for treating tuberculous pericarditis (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
large-scale multicentre clinical trial of intrapericardial fibrinolysis
in people with large pericardial effusions (NCT02673879).
Other treatments
We did not find eligible studies that assessed other potential treat-
ments for tuberculous pericarditis such as pericardiectomy, percu-
taneous drainage of the pericardium under local anaesthesia, cel-
lular therapy, use of repurposed drugs, or cytokine therapy.
Excluded studies
The excluded study is a cross-sectional analysis of the contempo-
rary use of adjunctive corticosteroids in the management of pa-
tients with tuberculous pericarditis in Africa (Wiysonge 2008).
Despite being observational in nature, this study is indexed in
electronic databases as a controlled trial. We have provided fur-
thermore details on this study in the ’Characteristics of excluded
studies’ table.
Studies awaiting assessment
One study is awaiting assessment, because the full-text article is in
Chinese and we do not yet have an English translation (Cui 2005).
In the study, consecutively recruited participants were “randomly”
assigned to intervention or control arms, but the study authors did
not provide any details about random sequence generation and
allocation concealment in the study abstract. We have provided
available details on this study in the ’Characteristics of studies
awaiting classification’ table.
Risk of bias in included studies
We have summarized our ’Risk of bias’ judgements for each in-
cluded trial in Figure 2 and Figure 3.
Figure 2. Risk of bias’ graph: review authors’ judgements about each Risk of bias’ item presented as
percentages across all included studies
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Figure 3. Risk of bias’ summary: review authors’ judgements about each Risk of bias’ item for each
included study
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Allocation
Five trials adequately generated the randomization sequence by
either a computer (Hakim 2000;Mayosi 2014; Liebenberg 2016),
or a random number list (Strang 2004a; Strang 2004b). The ad-
equacy of the generation of the randomization sequence was un-
clear in one trial (Reuter 2006), and inadequate in the other trial
(Schrire 1959). The concealment of allocation to treatment arms
was adequate in five trials (Hakim 2000; Strang 2004a; Strang
2004b; Mayosi 2014; Liebenberg 2016), and inadequate in two
trials (Schrire 1959; Reuter 2006).
Blinding
Participants, care providers, and outcome assessors were blinded
to treatment allocation in four trials (Hakim 2000; Strang 2004a;
Strang 2004b; Mayosi 2014). One study did not use blinding
(Schrire 1959). One study reported that “upon completion of the
research period, the blinding was unveiled”, but does not provide
details on how the blinding was done (Liebenberg 2016). In the
sixth study there was blinding of participants and care providers,
but it is unclear if outcome assessors were blind to treatment allo-
cation (Reuter 2006).
Incomplete outcome data
Loss to follow-up was minimal (0% to 5%) and non-differential
in four included trials (Hakim 2000; Strang 2004a; Strang 2004b;
Mayosi 2014).One trial did not adequately report losses to follow-
up (Schrire 1959), but losses to follow-upwere high (15% to 16%)
in two trials (Reuter 2006; Liebenberg 2016).
Selective reporting
One trial was free of reporting bias as the planned outcomes (as
indicated in the prospective trial registration [ClinicalTrials.gov
registration; NCT100810849] and published protocol) were re-
ported in the trial report (Mayosi 2014). It was unclear to us if the
remaining six studies (Schrire 1959; Hakim 2000; Strang 2004a;
Strang 2004b; Reuter 2006; Liebenberg 2016) were free from re-
porting bias; since none of the study protocols were available and
none of the trials were prospectively registered.
Other potential sources of bias
There is no evidence that the included studies had a high risk of
other sources of bias; apart from those described above.
Overall ’Risk of bias’ assessment
Based on the results of the ’Risk of bias’ assessments for the seven
domains above, we classified each included trial as either at low
risk of bias or high risk of bias. Four trials had a low risk of bias
(Hakim 2000; Strang 2004a; Strang 2004b; Mayosi 2014). The
other three included trials were each at high risk of bias (Schrire
1959; Reuter 2006; Liebenberg 2016).
Effects of interventions
See: Summary of findings for the main comparison
Corticosteroids for tuberculous pericarditis in HIV-negative
people; Summary of findings 2 Corticosteroids for tuberculous
pericarditis in HIV-positive people
1. Corticosteroids versus no corticosteroids in HIV-
negative people
1.1. Deaths from all causes
Four trials showed that corticosteroids may reduce deaths from
all causes in HIV-negative people (Strang 2004a; Strang 2004b;
Reuter 2006; Mayosi 2014), but the 95% CI includes the possi-
bility of both a large beneficial effect and a small increase in harm:
risk ratio (RR) 0.80, 95% CI 0.59 to 1.09; 660 participants, 4
trials; Analysis 1.1). We rated the certainty of the evidence as low
(Summary of findings for the main comparison).
1.2. Deaths from pericarditis
Four trials provided data on deaths from pericarditis in people
withoutHIV infection (Strang 2004a; Strang2004b;Reuter 2006;
Mayosi 2014). Pooling these data shows that corticosteroids prob-
ably reduce deaths from pericarditis: RR 0.39, 95% CI 0.19 to
0.80; 660 participants, 4 trials; Analysis 1.2.We rated the certainty
of the evidence as moderate (Summary of findings for the main
comparison).
1.3. Constrictive pericarditis
Based on two included trials, Reuter 2006 and Mayosi 2014, we
are uncertain whether corticosteroids reduce the risk of constric-
tive pericarditis in people without HIV infection: RR 0.72, 95%
CI 0.34 to 1.55; 281 participants, 2 trials; Analysis 1.3). This ev-
idence is of very low certainty (Summary of findings for the main
comparison).
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1.4. Repeat pericardiocentesis
Based on two included trials, Strang 2004b and Mayosi 2014,
corticosteroids may reduce the reaccumulation of fluid requiring
repeat drainage of the pericardium among HIV-negative people,
but the CIs include the possibility of both large beneficial effects
and a small increase in harm: RR 0.85, 95% CI 0.70 to 1.04; 492
participants, 2 trials; Analysis 1.4. We rated the certainty of the
evidence as low (Summary of findings for the main comparison).
1.5. Cancer
From the limited data on cancer reported by one trial (Mayosi
2014), we are uncertain about the effect of corticosteroids on the
risk of cancer (RR 0.85, 95% CI 0.05 to 13.80; 256 participants
(Analysis 1.5) in HIV-negative people, as the evidence is of very
low certainty (Summary of findings for the main comparison).
1.6. Hospitalization
Only one trial reported on this outcome (Mayosi 2014). We are
uncertain whether corticosteroids reduce the risk of hospitaliza-
tion in HIV-negative people (RR 0.98, 95% CI 0.57 to 1.70; 256
participants, 1 trial; Analysis 1.6), as the currently available evi-
dence is of very low certainty. We downgraded the evidence by
two for imprecision, as the CI ranges from clinically important
benefits to a large increase in harm. In addition, we downgraded
by one for selective reporting, given that data were only reported
by one of four trials that recruited HIV-negative people.
1.7. Pericardiectomy
Based on data from four trials (Schrire 1959; Strang 2004a; Strang
2004b; Reuter 2006), we are uncertain about the effects of cor-
ticosteroids on the risk of pericardiectomy in HIV-negative peo-
ple: RR 0.91, 95% CI 0.58 to 1.41; 432 participants, 4 trials;
Analysis 1.7). We rated the evidence to be of very low certainty.
We downgraded the evidence by two for imprecision, as the CI
ranges from large benefits to clinically important harms. We fur-
ther downgraded by one for study limitations, given that two of
the four trials were at high risk of bias.
1.8. Opportunistic infections
We do not know whether corticosteroids have an effect on oppor-
tunistic infections as the certainty of the evidence was assessed as
very low (RR 1.71, 95% CI 0.44 to 6.69; 256 participants, 1 trial;
Analysis 1.8). We downgraded the evidence by two for impreci-
sion, as the CI ranges from clinically important benefits to a large
increase in harm. In addition, we downgraded by one for selective
reporting, given that data were only reported by one of four trials
that recruited HIV-negative people.
2. Corticosteroids versus no corticosteroids in people
living with HIV infection
2.1. Deaths from all causes
Three included trials reported on this outcome (Hakim 2000;
Reuter 2006;Mayosi 2014). It is uncertainwhether corticosteroids
have an effect on the risk of deaths from any cause among people
living withHIV (RR 0.91, 95%CI 0.34 to 2.42; 575 participants,
3 trials; Analysis 2.1). This evidence is of very low certainty (
Summary of findings 2).
2.2. Deaths from pericarditis
Two trials provided data on the effects of corticosteroids on deaths
from pericarditis among 517 people living with HIV (Reuter
2006; Mayosi 2014). From these data, we are uncertain whether
corticosteroids have an effect on the risk of deaths frompericarditis
in HIV-positive people (RR 1.07, 95% CI 0.46 to 2.54; 517
participants, 2 trials; Analysis 2.2; very low certainty evidence;
Summary of findings 2).
2.3. Constrictive pericarditis
Currently available data from three included trials (Hakim 2000;
Reuter 2006;Mayosi 2014), show that corticosteroids may reduce
the risk of constrictive pericarditis among people living with HIV,
but the CIs include the possibility of both large beneficial effects
and a small increase in harm (RR 0.55, 0.26 to 1.16; 575 partic-
ipants, 3 trials; Analysis 2.3; low certainty evidence; Summary of
findings 2).
2.4. Repeat pericardiocentesis
Two trials reported data on the risk of reaccumulation of fluids
requiring repeat drainage of the pericardium in HIV-positive peo-
ple (Reuter 2006; Mayosi 2014). The combined data show that
corticosteroids may have little or no effect on this outcome (RR
1.02, 95%CI 0.89 to 1.18; 517 participants, 2 trials; Analysis 2.4;
low certainty evidence; Summary of findings 2).
2.5. Cancer
Based on currently available data from one included trial, Mayosi
2014, we are uncertain about the effects of corticosteroids on the
risk of cancer in people living with HIV (RR 1.62, 95% CI 0.27
to 9.77; 502 participants, 1 trial; Analysis 2.5; very low certainty
evidence; Summary of findings 2).
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2.6. Hospitalization
Based on one included trial, Mayosi 2014, corticosteroids may
reduce the risk of hospitalization in people living with HIV, but
the CIs include the possibility of both large beneficial effects and
a small increase in harm (RR 0.80, 95% CI 0.59 to 1.09; 502
participants, 1 trial; Analysis 2.6). This evidence is of low certainty.
We downgraded the evidence by one for imprecision, as the CI
ranges from clinically important benefits to little or no effect. In
addition, we downgraded by one for selective reporting, given that
data were only reported by one of three trials that recruited HIV-
negative people.
2.7. Pericardiectomy
There is insufficient evidence from one included trial, Reuter
2006, to determine whether corticosteroids have an effect on the
risk of pericardiectomy in people living with HIV (RR 2.10, 95%
CI 0.10 to 44.40; 15 participants, 1 trial; Analysis 2.7; very low
certainty evidence). We downgraded the evidence by two for im-
precision, as the CI ranges from substantial benefits to clinically
important harms. We further downgraded by one for selective re-
porting, given that data were only reported by one of three trials
that recruited HIV-negative people.
2.8. Opportunistic infections
Based on data from two included trials, Reuter 2006 and Mayosi
2014, it is uncertain whether corticosteroids have an effect on
the risk of opportunistic infections in HIV-positive people (RR
0.95, 95% CI 0.61 to 1.48; 517 participants, 2 trials; Analysis
2.8). We assessed the certainty of this evidence as very low. We
downgraded the evidence by two for imprecision, as the CI ranges
from substantial benefits to clinically important harms.We further
downgraded by one for study limitations, given that one of the
two trials has a high risk of bias.
3. Colchicine versus placebo
From the results of one trial among 33 HIV-positive people (
Liebenberg 2016), it is uncertain whether colchicine has an effect
on the risk of deaths fromall causes (RR0.74, 95%CI0.17 to 3.12;
Analysis 3.1) or constrictive pericarditis (RR 1.11, 95% CI 0.21
to 5.76; Analysis 3.2). We assessed the certainty of the evidence
for each outcome as very low. We downgraded the evidence by
two for imprecision, as the CI ranges from substantial benefits to
clinically important harms. We further downgraded by one for
study limitations, given that the included trial has a high risk of
bias.
4. M. indicus pranii versus placebo
One trial evaluated the effects of M. indicus pranii immunother-
apy in a two-by-two factorial design among 1250 people aged 18
years or older in Zimbabwe, South Africa, Sierra Leone, Uganda,
Nigeria, Mozambique, Malawi, and Kenya (Mayosi 2014).
The trial reveals uncertainty about the effects ofM. indicus pranii
on deaths from all causes (RR 1.07, 95%CI 0.56 to 2.03; Analysis
4.1), deaths from pericarditis (RR 1.50, 95% CI 0.44 to 5.15;
Analysis 4.2), constrictive pericarditis (RR 1.56, 95% CI 0.71 to
3.42; Analysis 4.3), repeat pericardiocenthesis (RR 1.21, 95% CI
0.96 to 1.52; Analysis 4.4), cancer (RR 3.03, 95% CI 0.12 to
75.37; Analysis 4.5), hospitalization (RR 1.22, 95% CI 0.70 to
2.13; Analysis 4.6), and opportunistic infections (RR 0.67, 95%
CI from 0.11 to 3.90; Analysis 4.7) in HIV-negative people. The
certainty of the evidence was very low for all the outcomes. We
downgraded the evidence by two for imprecision, as the CIs for all
outcomes range from substantial benefits to clinically important
harms. We further downgraded by one for possibility of publica-
tion bias, as only one trial has so far reported data on this inter-
vention.
Similar to HIV-negative people, among people living with HIV,
we are also uncertain whether M. indicus pranii has an effect on
the risk of deaths from all causes (Analysis 5.1), deaths from peri-
carditis (Analysis 5.2), constrictive pericarditis (Analysis 5.3), re-
peat pericardiocenthesis (Analysis 5.4), cancer (Analysis 5.5), hos-
pitalization (Analysis 5.6), or opportunistic infections (Analysis
5.7) as the current evidence is of very low certainty. There were
too few HIV-positive patients on antiretroviral treatment to assess
the effects of M. indicus pranii in this group of participants. We
downgraded the evidence by two for imprecision, as the CIs for all
outcomes range from clinically important benefits to substantial
increases in harms. We further downgraded by one for possibility
of publication bias, as only one trial has so far reported data on
this intervention.
5. Open surgical drainage for effusion versus no
drainage
One trial, conducted in South Africa, assessed the effects of routine
open surgical drainage on admission to hospital compared to no
intervention among 122 participants with tuberculous pericardial
effusion (Strang 2004b). This trial started before the onset of the
HIV epidemic in South Africa and, although no HIV testing was
done, we have assumed the participants to be HIV-negative.
The results of the trial show that open surgical drainage may re-
duce the risk of reaccumulation of fluid requiring repeat pericar-
diocentesis in people without HIV infection (RR 0.23, 95% CI
0.07 to 0.76; Analysis 6.3). However, the intervention may make
little or no difference to any other outcome measured in the study;
including deaths from all causes (Analysis 6.1), deaths from peri-
carditis (Analysis 6.2), and pericardiectomy (Analysis 6.4). We
rated the certainty of the evidence for each of these outcomes as
low. We downgraded the evidence by one for imprecision, as the
CIs for most outcomes range from clinically important benefits to
little or no effect.We further downgraded by one for possibility of
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publication bias, as only one trial has so far reported data on this
intervention.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Population: HIV-posit ive people with tuberculous pericardit is. Most pat ients (80%) not on ant iretroviral drugs
Settings: any sett ing
Intervention: cort icosteroids
Comparison: placebo
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Placebo Corticosteroids
Death f rom all causes 17 per 100 15 per 100
(6 to 40)
RR 0.91
(0.34 to 2.42)
575
(3 trials)
⊕©©©
very low1,2
It is uncertain whether
steroids have an ef fect
on the risk of deaths
f rom all causes among
people living with HIV
Death f rom pericardit is 4 per 100 4 per 100
(2 to 10)
RR 1.07
(0.46 to 2.54)
517
(2 trials)
⊕©©©
very low1,3
It is uncertain whether
steroids have an ef fect
on the risk of deaths
f rom pericardit is among
people living with HIV
Constrict ive pericardi-
t is
6 per 100 4 per 100
(2 to 7)
RR 0.55
(0.26 to 1.16)
575
(3 trials)
⊕⊕©©
low1
Steroids may reduce the
risk of developing con-
strict ion among people
living with HIV
Repeat pericardiocen-
tesis
60 per 100 61 per 100
(53 to 71)
RR 1.02
(0.89 to 1.18)
517
(2 trials)
⊕⊕©©
low3,5
Steroids may have lit t le
or no ef fect on the risk
of repeat pericardiocen-
tesis among people liv-
ing with HIV
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Cancer 1 per 100 1 per 100
(0 to 8)
RR 1.62
(0.27 to 9.77)
502
(1 trial)
⊕©©©
very low1,3
It is uncertain whether
steroids have an ef -
fect on the risk of can-
cer among people living
with HIV
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1We downgraded by 2 for imprecision: the CI ranges f rom substant ial clinical benef its to substant ial harm.
2We downgraded by 1 for unexplained heterogeneity (Chi² = 3.82, df = 1 (P = 0.05); I² stat ist ic = 74%).
3We downgraded by 1 for select ive report ing: only 2 of the 3 studies that recruited HIV-posit ive people reported data.
4We downgraded by 1 for study lim itat ions: 1 study had a high risk of bias.
5We downgraded by 1 for imprecision: the CI ranges f rom a small benef icial ef fect to clinically important harms.
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D I S C U S S I O N
Summary of main results
This is an update of aCochrane Reviewpublished in 2002 (Mayosi
2002). Seven randomized controlled trials (RCTs) met the inclu-
sion criteria of this review, and all were conducted in sub-Saha-
ran Africa. The 2002 review included four trials (Schrire 1959;
Strang 2004a; Strang 2004b; Hakim 2000). In addition to up-
dated outcome data from two previously included trials (Strang
2004a; Strang 2004b), we have included three new trials in this
update (Reuter 2006;Mayosi 2014; Liebenberg 2016). Four stud-
ies are at low risk of bias (Hakim 2000; Strang 2004a; Strang
2004b; Mayosi 2014), and three are at high risk of bias (Schrire
1959;Reuter 2006; Liebenberg 2016). The included trials enrolled
1959 participants (54% of them HIV-positive). Six trials evalu-
ated corticosteroids (Schrire 1959; Hakim 2000; Strang 2004a;
Strang 2004b; Reuter 2006;Mayosi 2014), and one each evaluated
colchicine (Liebenberg 2016), M. indicus pranii immunotherapy
(Mayosi 2014), and open surgical drainage of pericardial effusion
(Strang 2004b).
The key findings from these studies are as follows.
• In people without HIV infection, corticosteroids probably
reduce deaths from pericarditis (moderate certainty evidence) and
may reduce deaths from all causes and the need for repeat
pericardiocentesis (low certainty evidence). However, it is
uncertain whether corticosteroids have an effect on any other
outcome among HIV-negative people (very low certainty
evidence) (Summary of findings for the main comparison).
• In people living with HIV and not on antiretroviral drugs,
corticosteroids may reduce constrictive pericarditis and
hospitalization (low certainty evidence). However, corticosteroids
may make little or no difference to the need for repeat
pericardiocentesis (low certainty evidence) and it is uncertain
whether the intervention has an effect on deaths or any other
outcome in HIV-positive people (very low certainty evidence)
(Summary of findings 2).
• It is uncertain whether colchicine has an effect on any
outcome among HIV-positive people (very low certainty
evidence). All participants were on antiretroviral treatment.
• It is uncertain whetherM. indicus pranii has an effect on
the risk of deaths or any other outcome, regardless of HIV status
(very low certainty evidence).
• In people without HIV infection, routine open surgical
drainage for effusion may reduce the need for repeat
pericardiocentesis, but may make little or no difference to any
other outcome (low certainty evidence).
Overall completeness and applicability of
evidence
We found that adjunctive corticosteroids may lead to a modest
relative reduction of about 20% on the risk of all-cause mortality
among HIV-negative people. Before the biggest trial on the sub-
ject was published (Mayosi 2014), two small trials, Strang 2004a
and Strang 2004b, had previously suggested that adjunctive cor-
ticosteroids may reduce mortality by 35% among HIV-negative
patients (Ntsekhe 2003). Regarding people living with HIV, cur-
rently available data suggest a relative reduction of 9% in mor-
tality, but the CI ranges very widely from a 66% relative reduc-
tion to a massive 142% relative increase in mortality. Before the
publication of the big trial, Mayosi 2014, data from one small
trial suggested that the use of adjunctive corticosteroids among
HIV-positive people with tuberculous pericarditis would result in
a 50% relative reduction in mortality (Hakim 2000).
Evidence from small early trials on health interventions is of-
ten untrustworthy (Wiysonge 2014). An examination of more
than 85,000 binary-outcome forest plots from more than 3000
CochraneReviews found thatmost large treatment effects emerged
from small trials and when additional larger trials were performed,
the effect sizes typically became much smaller (Pereira 2012).
Apart from corticosteroids, we found only one trial each that
assessed the effects of colchicine (Liebenberg 2016), M. indicus
pranii immunotherapy (Mayosi 2014), and open surgical drainage
(Strang 2004b).
There is unclear evidence regarding the relationship between cor-
ticosteroids, M. indicus pranii, and increased rates of cancer. This
merits further study. One trial found an association between
increased rates of cancer among people randomized to receive
bothM. indicus pranii and corticosteroids (Mayosi 2014). How-
ever, this trial was inadequately powered to determine whether this
effect was due to corticosteroids alone,M. indicus pranii alone, or
a synergistic action between the two interventions.
We aimed to identify the optimal drug combination and treat-
ment duration, but found no eligible trials. This is an important
question in the light of the recent demonstration that the concen-
trations of rifampicin, ethambutol, and pyrazinamide in pericar-
dial fluid based on current treatment regimens were dramatically
low and below the minimum inhibitory concentrations of M. tu-
berculosis (Shenje 2015). Furthermore, patients with culture-con-
firmed tuberculous pericarditis have a high bacillary burden, and
this bacterial burden drives mortality (Pasipanodya 2015). There-
fore the design of a highly bactericidal regimen for this condition
is needed, and testing of its effectiveness in RCTs.
Currently there are no RCTs studying the issue of timing of peri-
cardiectomy in people with a diagnosis of tuberculous constrictive
pericarditis. The current recommendation of pericardiectomy for
persistent signs of constriction after at least six weeks of antituber-
culous chemotherapy is based on expert opinion (Commerford
1991; Mutyaba 2014).
In addition, we found no eligible completed trials that assessed
the effects of percutaneous drainage of the pericardium under lo-
cal anaesthesia, intrapericardial fibrinolysis (Augustin 2011), nor
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novel therapies such as cellular therapy, use of repurposed drugs,
and cytokine therapy (Zumla 2015).
Quality of the evidence
We included seven RCTs in this review. In the GRADE system,
RCTs without important limitations constitute high certainty evi-
dence.However, the systemconsiders five factors that can lower the
certainty of the evidence: study limitations, heterogeneity, indi-
rectness, imprecision, and publication bias (Balshem 2011). Four
included studies were well-conducted RCTs (Hakim 2000; Strang
2004a; Strang 2004b; Mayosi 2014), at a low overall risk of bias
(Figure 2; Figure 3). Each of the remaining three trials had a high
overall risk of bias (Schrire 1959; Reuter 2006; Liebenberg 2016).
These study limitations, as well as the imprecision of most effects,
had an important impact on our rating of the certainty of the evi-
dence (see the ’Summary of findings’ tables: Summary of findings
for the main comparison; Summary of findings 2).
Potential biases in the review process
We minimized potential biases in the review process by adher-
ing to the guidelines of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We conducted comprehen-
sive searches of both peer-reviewed and grey literature, without
limiting the searches to a specific language. Two review authors in-
dependently assessed study eligibility, extracted data, and assessed
the risk of bias in each included trial. When a potentially eligible
study was conducted by review co-authors, we requested indepen-
dent researchers (who were not involved in the article under con-
sideration) to assess eligibility and (if eligible for inclusion) extract
data (Kliner 2014).
Agreements and disagreements with other
studies or reviews
The previously published version of this Cochrane Review,Mayosi
2002, found that corticosteroids could have important clinical
benefits in both HIV-negative and HIV-positive people. How-
ever, the three included trials were too small to demonstrate a sig-
nificant effect (Hakim 2000; Strang 2004a; Strang 2004b). The
review authors also included one trial that examined open surgical
drainage compared with conservative management, and showed
that surgery relieved cardiac tamponade (Strang 2004b). A year
later, Ntsekhe and colleagues published a systematic review of
the effectiveness of adjunctive corticosteroids in tuberculous peri-
carditis, in which they concluded that corticosteroids could have
large beneficial effects on mortality and morbidity in tuberculous
pericarditis but published trials were too small to be conclusive
(Ntsekhe 2003). No other systematic review of treatments for tu-
berculous pericarditis has been published since then.
Imazio 2015 published a systematic review on the causes, diagno-
sis, therapy, prevention, and prognosis of pericarditis. However,
the authors focused the treatment component of the review on in-
terventions for idiopathic and viral pericarditis in North America
and Europe.
This Cochrane Review is therefore themost comprehensive review
to date on interventions for treating tuberculous pericarditis.The
review’s findings are slightly different to the largest trial ever com-
pleted, authored by some of the authors of this review, which
showed no significant difference for corticosteroids on a compos-
ite outcome reflecting benefit, and a slight increase in HIV-associ-
ated cancer . The finessing of the results and the interpretation is
probably due to multiple factors, including combining with other
studies; and re-analysing the the original trial data stratified by
HIV status.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review shows that corticosteroids and open surgical drainage
have evidence of benefit in people with tuberculous pericarditis.
In HIV-negative people, corticosteroids probably reduce deaths
from pericarditis (moderate certainty evidence) and may reduce
deaths from all causes (low certainty evidence) and the need for re-
peat pericardiocentesis (low certainty evidence); while open surgical
drainage may reduce the subsequent need for pericardiocentesis
(low certainty evidence).
In the treatment of people living with HIV not on antiretroviral
drugs, corticosteroids may reduce constrictive pericarditis (low cer-
tainty evidence) and hospitalizations (low certainty evidence); with
little or no effect on deaths (low certainty evidence).
Implications for research
The relationship between corticosteroids, immunomodulators,
and increased rates of cancer needs to be investigated further. In
addition, high-quality randomized trials are needed on percuta-
neous drainage of the pericardium under local anaesthesia, the
timing of pericardiectomy in tuberculous constrictive pericarditis,
new antibiotic regimens, cellular therapy, use of repurposed drugs,
and cytokine therapy.
We will update this Cochrane Review when the ongoing trial of
intrapericardial fibrinolysis is published (NCT02673879).
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hakim 2000
Methods Computer-generated randomization list
Double blind placebo controlled trial
Participants 58 HIV-positive participants who were on antituberculous chemotherapy for suspected
tuberculous pericarditis
Inclusion criteria: (a) age 18 to 55 years; (b) residence in Harare city to ensure good
follow up; (c) HIV seropositive; (d) no diagnosis of tuberculosis within the past two
years; (e) large pericardial effusion on echocardiography (> 1 cm anteriorly and > 1 cm
posteriorly; and (f ) pericardial aspirate with > 50% lymphocytes and protein content >
30 g/L
Exclusion criteria: (a) antituberculous treatment started more than 48 hours before re-
cruitment; (b) corticosteroid treatment within previous one month; (c) presence of Ka-
posi’s sarcoma or any other malignancy; (d) coexisting life threatening disease; (e) bac-
terial pneumonia; (f ) pregnancy; (g) cavitating pulmonary tuberculosis; and (h) other
causes of pericardial effusion
“All patients received a standard short course anti tuberculous regimen in accordancewith
national guidelines. This included rifampicin, isoniazid, pyrazinamide, and ethambutol
for two months, followed by rifampicin and isoniazid for a further four months in
standard doses.”
Interventions Intervention
• Prednisolone for the first 6 weeks of antituberculous chemotherapy.
• Dose for adults: 60 mg for the first week, and tapering by 10 mg every week.
Control
• Placebo.
Outcomes Primary outcomes
• Death.
• Resolution of pericardial effusion.
Secondary outcomes
• Resolution of pretreatment symptoms and signs, and ECG changes.
• Corticosteroid-related adverse effects.
Notes Study location: Harare, Zimbabwe
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was achieved by the use of
a computer generated randomisation list”
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Hakim 2000 (Continued)
Allocation concealment (selection bias) Low risk “Prednisolone/placebo packages were pre-
pared according to the randomisation list,
but labelled with the study number only. A
package consisted of six well labelled bot-
tles each containing the number of tablets
required in each of the six weeks of the in-
tervention. Eligible patients were given a
drug package consecutively working down
the randomisation list.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Clinicians and patients were blinded to
the identity of the tablets. A randomisation
code list was kept sealed and was released
at the end of the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Two cardiologists with extensive experience
of echocardiography in this setting per-
formed all examinations. “Clinicians and
patients were blinded to the identity of the
tablets. A randomisation code list was kept
sealed and was released at the end of the
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up data was available on all 58 en-
rolled participants
Selective reporting (reporting bias) Unclear risk The study protocol was not available and
there is no earlier methods paper listing the
prespecified outcomes
Other bias Low risk There is no evidence that the study had
any additional biases to the onesmentioned
above
Liebenberg 2016
Methods Participants “were randomised to an intervention and control group using a web-based
computer system that ensured assignment concealment”
“Upon completion of the research period, the blinding was unveiled and data were
presented for statistical analysis”
Participants 33 HIV-positive people with definite or probable tuberculous pericarditis at a secondary
level hospital in the Northern Cape of South Africa
All participants received standard treatment according to the South African National
Tuberculosis Management Guidelines, that is weight-adjusted antituberculosis drugs
and oral corticosteroids for 4 weeks. Participants also had pericardial “aspiration until
dryness”, and antiretroviral therapy
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Liebenberg 2016 (Continued)
Interventions Intervention
• Colchicine 1.0 mg per day for 6 weeks.
Comparison
• Placebo for 6 weeks.
Participants were followed up with serial echocardiography for 16 weeks
Outcomes Primary outcome
• Constrictive pericarditis.
Notes Study location: Kimberley, South Africa.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The mention of an internet-based com-
puter system implies use of a computer-
generated randomization sequence
Allocation concealment (selection bias) Low risk Participants “were randomised to an inter-
vention and control group using a web-
based computer system that ensured assign-
ment concealment”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study authors reported that “Upon
completion of the research period, the
blinding was unveiled and data were pre-
sented for statistical analysis”, but did not
provide further details of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study reported that blinding was un-
veiled only after completion of the follow-
up period, when presenting data to the
statistician
Incomplete outcome data (attrition bias)
All outcomes
High risk In this study, 5/33 (15.15%) participants
were lost to follow-up
Selective reporting (reporting bias) Unclear risk We do not have access to the study proto-
col and are unable to comment on whether
there was selective reporting of outcomes
in this study
Other bias Low risk There was no evidence of other sources of
bias in the study.
27Interventions for treating tuberculous pericarditis (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Mayosi 2014
Methods Computer-generated randomization list
Double-blind placebo-controlled 2 × 2 factorial study
Participants 1400 participants (two-thirds HIV-positive) 18 years of age or older, with a pericardial
effusion confirmed by echocardiography, evidence of definite or probable tuberculous
pericarditis, and had begun antituberculous treatment less than 1 week before enrolment
“Trial participants received antimicrobial treatment for tuberculosis and antiretroviral
treatment for HIV according to World Health Organization (WHO) guidelines; man-
agement during the course of the trial was revised as recommended treatment practices
evolved”
Interventions Intervention 1
• Prednisolone for 6 weeks at a dose of 120 mg per day in the first week, 90 mg per
day in the second week, 60 mg per day in the 3rd week, 30 mg per day in the 4th week,
15 mg per day in the 5th week, and 5 mg per day in the 6th week.
Control 1
• Identical placebo for 6 weeks at a dose of 120 mg per day in the 1st week, 90 mg
per day in the 2nd week, 60 mg per day in the 3rd week, 30 mg per day in the 4th
week, 15 mg per day in the 5th week, and 5 mg per day in the 6th week.
Intervention 2
• M. indicus pranii preparation (CADI-Mw injection, Cadila Pharmaceuticals) in 5
doses: at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The
1st dose was given as 2 injections of 0.1 mL (containing 0.5 × 109 organisms) in each
deltoid region of the upper arm; the 4 subsequent doses were given as a single injection
of 0.1 mL.
Control 2
• Identical placebo in 5 doses: at the time of enrolment and at 2 weeks, 4 weeks, 6
weeks, and 3 months. The 1st dose was given as 2 injections of 0.1 mL in each deltoid
region of the upper arm; the 4 subsequent doses were given as a single injection of 0.1
mL.
Outcomes Primary outcome
• Composite of death or 1st occurrence of cardiac tamponade requiring
pericardiocentesis or constrictive pericarditis.
Secondary outcomes
• Individual components of the primary outcome.
• Hospitalization.
Safety outcomes
• Opportunistic infections.
• Cancer.
• CD4+ T-lymphocyte cell count (measure of immunosuppression) and immune
reconstitution inflammatory syndrome (in HIV-positive).
Notes Study location: multiple sites in South Africa, Mozambique, Malawi, Uganda, Sierra
Leone, Zimbabwe, Kenya, and Nigeria
Risk of bias
Bias Authors’ judgement Support for judgement
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Mayosi 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomization list.
Allocation concealment (selection bias) Low risk Central allocation, stratified by centre, with
random block sizes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both prednisolone and M. indicus pranii
preparation had identical placebos.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A committee of clinicians blinded to treat-
ment allocation (the Outcomes Adjudica-
tion Committee) adjudicated all primary
and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants were analysed in groups to
which they were randomized, regardless of
how much of the intended intervention
they actually received. Primary outcome
datawere known for 1371 of 1400 (97.9%)
participants in the prednisolone-placebo
comparison; with no significant differences
between prednisolone (688/706;. 97.5%)
and placebo (683/694; 98.4%) arms. For
theM. indicus pranii - placebo comparison,
primary outcome data were available for
1223 of 1250 participants (97.8%); with
no significant differences betweenM. indi-
cus pranii (611/625; 97.8%) and placebo
(612/625; 97.9%).
Selective reporting (reporting bias) Low risk The study authors reported the outcomes
planned for in the prospective trial registra-
tion (ClinicalTrials.gov registration num-
ber NCT100810849) and published pro-
tocol in the trial report
Other bias Low risk There was no evidence of other biases in
the study.
Reuter 2006
Methods Computer-generated randomization list
Double-blind placebo-controlled study
Participants 57 participants, aged 17 to 66 years, with large pericardial effusions on echocardiogra-
phy, pericardial aspirate with protein content > 30 g/L, and pericardial fluid adenosine
deaminase (ADA) activity > 35 U/L; 23 females and 34 males; 40 had microbiological
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Reuter 2006 (Continued)
or histological evidence of TB or both, and 17 patients were diagnosed by clinical and
supportive laboratory data. 21 (37.0%) were HIV-positive
“A standard short-course anti-tuberculous regimen was initiated according to national
guidelines, namely a combination of rifampicin, isoniazid, pyrazinamide and ethambutol
for twomonths, followed by rifampicin and isoniazid for a further four months...Patients
were discharged on anti-tuberculous therapy and pyridoxine, with or without adjunctive
prednisone. HIV-positive patients also received daily oral cotrimoxazole; due to the
prevailing national policy at the time of this study, none of these patients received
antiretroviral therapy”
Interventions Intervention 1
• 200 mg (5 mL) intrapericardial triamcinolone hexacetonide. Triamcinolone was
injected directly into the pericardium just prior to the removal of the indwelling
catheter. Due to limited resources, an oral placebo was not used in conjunction with
the intrapericardial triamcinolone. 17 participants were in this arm, 6 (35%) were
HIV-positive.
Intervention 2
• Oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution). Oral
prednisone was started at 60 mg/day for 4 weeks, followed by 30 mg/day for 4 weeks,
15 mg/day for 2 weeks and 5 mg/day for 1 week. There were 16 participants in this
arm, 9 (56%) were HIV-positive.
Control
• Placebo (5 mL intrapericardial 0.9% saline). 24 participants were included in this
arm, and 6 (25%) were HIV-positive.
Outcomes Primary outcome
• All-cause mortality.
Secondary outcomes
• Death attributed to pericarditis.
• Disability related to pericardial disease at 1 year (defined as a history of restricted
physical activity using New York Heart Association functional classification.
• Effusive constriction.
• Fibrous constrictive pericarditis requiring pericardiectomy.
Notes Study location: Cape Town, South Africa.
We excluded data from the intrapericardial triamcinolone arm from this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participantswere “randomly assigned as per
a predetermined randomisation schedule
for 100 patients on a 3:3:4 basis. Numbers
were drawn from a hat, stored on a list on
a computer and provided to the treating
physician with the assigned treatment by a
non-clinical administrator.”
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Reuter 2006 (Continued)
Allocation concealment (selection bias) High risk An unblinded, independent physician ad-
ministered one of the three randomly as-
signed treatment options
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The randomisation code remained con-
cealed and was not revealed to the investi-
gators or the study subjects until comple-
tion of the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study states that outcomes were as-
sessed using a combination of clinical and
echocardiographic features, but there is no
mentionof blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Nine (16.0%) participants were lost to fol-
low-up.
Selective reporting (reporting bias) Unclear risk We do not have access to the study proto-
col and are unable to comment on whether
there was selective reporting of outcomes
in this study
Other bias Low risk No evidence of other biases
Schrire 1959
Methods Alternate allocation of 28 participants to adjuvant steroids or no steroids
Participants 28 participants who were on antituberculous chemotherapy for suspected tuberculous
pericarditis. The trial authors did not provide the characteristics of the included partic-
ipants, and did not specify the antituberculous drugs used
Interventions Intervention
• Cortisone with a loading dose of 300 mg and maintenance dose of 100 mg daily
for several weeks was prescribed for 14 participants. At a later date, prednisolone 60
mg/day with a maintenance dose of 20 mg was substituted.
Control
• No corticosteroids.
The trial authors did not specify the length of follow-up.
Outcomes Constriction requiring pericardiectomy
Notes Study location: Cape Town, South Africa
Risk of bias
Bias Authors’ judgement Support for judgement
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Schrire 1959 (Continued)
Random sequence generation (selection
bias)
High risk The trial authors performed randomization
by alternation.
Allocation concealment (selection bias) High risk There was no allocation concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial did not perform any blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk There was no evidence of blinding of out-
come assessors.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors did not adequately report
losses to follow-up
Selective reporting (reporting bias) Unclear risk The study protocol was not available.
Other bias Low risk There was no evidence of other sources of
bias.
Strang 2004a
Methods Central randomization
Double blind placebo-controlled study
Participants 143 participants with suspected tuberculous constrictive pericarditis aged 5 years and
older. The participants in the treatment and control groups were well-matched in terms
of clinical characteristics and completion of antituberculous chemotherapy
“Those consenting to take part were all prescribed the same 6-month standard antitu-
berculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide daily for 14
weeks as an in-patient, followed by isoniazid and rifampicin daily up to 6 months.”
Interventions Intervention
• Prednisolone for the first 11 weeks of antituberculous chemotherapy. The dose for
children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to
8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. Regarding children
aged 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5
mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the
first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 1.
Control
• Matching placebo.
Outcomes • Death.
• Death from pericarditis.
• Favourable clinical status at 24 months.
• Pericardiectomy.
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Strang 2004a (Continued)
Notes Study location: Umtata, South Africa
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used a random number
list.
Allocation concealment (selection bias) Low risk The trial authors used central randomiza-
tion.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Particianpts and care providers were
blinded to treatment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators, including outcome assessors,
were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk During 10 years of follow-up, 1 participant
(1.4%) was lost to follow-up in the pred-
nisolone group and 2 participants (2.7%)
in the placebo group
Selective reporting (reporting bias) Unclear risk There was no study protocol available.
Other bias Low risk There was no evidence of other sources of
bias.
Strang 2004b
Methods Central randomization
Double blind placebo-controlled study
Factorial design
Participants 240 participants aged 5 years or more diagnosed as having active tuberculous pericardial
effusion. The participants in the treatment and control groups were well-matched in
terms of their clinical characteristics and completion of antituberculous chemotherapy
“Those consenting to take part were all prescribed the same 6-month standard antitu-
berculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide daily for 14
weeks as an in-patient, followed by isoniazid and rifampicin daily up to 6 months.”
Interventions Intervention 1
• Complete open surgical drainage on admission.
Control 1
• No open drainage.
Intervention 2
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Strang 2004b (Continued)
• Prednisolone for the first 11 weeks of antituberculous chemotherapy. The dose for
children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to
8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. Regarding children
aged 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5
mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the
first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 1.
Control 2
• Matching placebo.
Outcomes • Death.
• Death from pericarditis.
• Favourable clinical status at 24 months.
• Tamponade requiring pericardiocentesis.
• Constriction.
• Pericardiectomy.
Notes Study location: Umtata, South Africa
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used a random number list to per-
form random sequence generation
Allocation concealment (selection bias) Low risk The trial authors performed central ran-
domization.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The participants and investigators were
blinded to the steroid component, but not
to the surgical drainage component
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “For patients who died, information was
obtained on cause of death from hospital
records, relatives, or other contacts. All the
deaths were reviewed by an independent as-
sessor without knowledge of the treatment
group, and where possible, he classified the
cause.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/117 (4.3%) participants were lost to fol-
low-up in the prednisolone group com-
pared to 7/119 (5.9%) in the placebo group
2/64 (3.1%) participants were lost to fol-
low-up in the drainage group compared to
3/58 (5.2%) in the no drainage group
Selective reporting (reporting bias) Unclear risk There was no study protocol available.
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Strang 2004b (Continued)
Other bias Low risk There was no evidence of other sources of
bias.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Wiysonge 2008 Although this study is indexed in electronic databases as a controlled trial, it is actually a cross-sectional study of
the contemporary use of adjunctive steroids by physicians treating patients with tuberculous pericarditis. We thus
excluded it from this review due to ineligible study design
Characteristics of studies awaiting assessment [ordered by study ID]
Cui 2005
Methods Consecutively recruited participants were “randomly” assigned to intervention or control arms, but no further details
about random sequence generation and allocation concealment are not provided in the abstract. The length of
following-up varied from 8 to 120 months (mean 56.8 ± 29.0 months)
Participants Ninety-four participants with infectious exudative pericarditis (34 with purulent pericarditis and 60 with tuberculous
pericarditis); disease course less than 1 month; 44 males and 50 females; age 9 to 66 years (mean 45.4 ± 14.7 years);
consecutively enrolled between 1993 to 2002 in China. The hospital and city are not specified
Interventions Intervention arm: intrapericardial urokinase along with conventional treatment in intervention arm, or conventional
treatment alone (including pericardiocentesis and drainage) in the control arm. The dosage of urokinase ranged from
200,000 to 600,000 U (mean 320,000 ± 70,000 U)
Outcomes Pericardial constriction, as detected by pericardiography with sterilized air and diatrizoate meglumine as contrast
media (in the short-tem) and telephonic survey and echocardiographic examination (in the long-term)
Notes Study published in Chinese. Only the abstract is currently available in English
Characteristics of ongoing studies [ordered by study ID]
NCT02673879
Trial name or title The Second Investigation of the Management of Pericarditis (IMPI-2) Trial
Methods Study design: randomized trial
Intervention model: parallel assignment
Blinding: single blind (outcomes assessor)
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NCT02673879 (Continued)
Participants The study plans to enrol 2176 participants.
Inclusion criteria
• Age ≥ 18 years of age.
• Confirmed large pericardial effusion on echocardiography (that is, echo free space ≥ 1 cm anterior to
the right ventricle of the heart in diastole).
• Willingness to participate for the full duration of the trial (that is, 12 months).
• Provision of written informed consent.
Exclusion criteria
• Age < 18 years.
• Uraemic pericarditis (that is, urea > 21.4 mmol/L).
• Thrombocytopenia (that is, < 100,000 platelets/µL).
• Presence of a contraindication to the administration of a fibrinolytic agent (major haemorrhage or
major trauma; coincidental stroke; major surgery in the previous 5 days; blood pressure > 200/100 mmHg).
Interventions Intervention: complete percutaneous pericardial drainage facilitated by intrapericardial alteplase (recombi-
nant human tissue-type plasminogen activator)
Comparison: conventional pericardiocentesis.
Outcomes Primary outcomes
• Composite outcome of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.
Secondary outcomes
• Major bleeding.
• Clinically relevant non-major bleeding.
• Any bleeding.
• Any other form of bleeding that is not covered by safety outcomes 1-3.
• Other adverse events.
• Any other adverse events.
• Persistent pericardial effusion without cardiac tamponade.
• Recurrent pericardial effusion without cardiac tamponade.
• Hospitalization for any cause; and death from any cause.
• Cardiac tamponade requiring pericardiocentesis.
• Constrictive pericarditis.
• Death from any cause.
• Proportion with proven tuberculosis.
• Time to diagnosis of proven tuberculosis.
• Proportion with proven tuberculosis on novel tests who are not put on treatment.
• Diagnostic accuracy of novel tests of tuberculosis.
• Drug-resistant tuberculosis.
• Specific diagnosis of tuberculous pericarditis.
• Time to diagnosis of specific pericardial disease.
Starting date The study started in February 2016, with the planned completion date as January 2019
Contact information Principal investigator: Professor Bongani M, Mayosi, University of Cape Town, Cape Town, South Africa
Contacts:
• Shaheen Pandie: Phone +27823199030; Email: s.pandie@uct.ac.za
• Veronica Francis: Phone +27832449895; Email: veronica.francis@uct.ac.za
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NCT02673879 (Continued)
Notes Sponsor: University of Cape Town, South Africa.
Collaborators:Walter Sisulu University, South Africa; Population Health Research Institute, Canada
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D A T A A N D A N A L Y S E S
Comparison 1. Steroids versus placebo in HIV-negative people
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths from all causes 4 660 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.59, 1.09]
2 Deaths from pericarditis 4 660 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.19, 0.80]
3 Constrictive pericarditis 2 281 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.34, 1.55]
4 Repeat pericardiocentesis 2 492 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.70, 1.04]
5 Cancer 1 256 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.05, 13.80]
6 Hospitalization 1 256 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.57, 1.70]
7 Pericardiectomy 4 432 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.58, 1.41]
8 Opportunistic infections 1 256 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.44, 6.69]
Comparison 2. Steroids versus placebo in HIV-positive people
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths from all causes 3 575 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.34, 2.42]
2 Deaths from pericarditis 2 517 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.46, 2.54]
3 Constrictive pericarditis 3 575 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.26, 1.16]
4 Repeat pericardiocentesis 2 517 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.89, 1.18]
5 Cancer 1 502 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [0.27, 9.77]
6 Hospitalization 1 502 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.59, 1.09]
7 Pericardiectomy 1 15 Risk Ratio (M-H, Fixed, 95% CI) 2.1 [0.10, 44.40]
8 Opportunistic infections 2 517 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.48]
Comparison 3. Colchicine versus placebo in HIV-positive people
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death from all causes 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Constrictive pericarditis 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
38Interventions for treating tuberculous pericarditis (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 4. M. indicus pranii versus placebo in HIV-negative people
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths from all causes 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.56, 2.03]
2 Deaths from pericarditis 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.44, 5.15]
3 Constrictive pericarditis 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.71, 3.42]
4 Repeat pericardiocentesis 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.96, 1.52]
5 Cancer 1 190 Odds Ratio (M-H, Fixed, 95% CI) 3.03 [0.12, 75.37]
6 Hospitalization 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.70, 2.13]
7 Opportunistic infections 1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 3.90]
Comparison 5. M. indicus pranii versus placebo in HIV-positive people
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths from all causes 1 414 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.69, 1.60]
2 Deaths from pericarditis 1 414 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.16, 1.67]
3 Constrictive pericarditis 1 414 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.33, 1.60]
4 Repeat pericardiocentesis 1 414 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.80, 1.10]
5 Cancer 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Hospitalization 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Opportunistic infections 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. Surgical drainage versus no intervention in HIV-negative people
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death from all causes 1 122 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.52, 2.20]
2 Death from pericarditis 1 122 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.16, 2.91]
3 Repeat pericardiocentesis 1 122 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.07, 0.76]
4 Pericardiectomy 1 122 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.14, 2.18]
39Interventions for treating tuberculous pericarditis (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.1. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 1 Deaths from all
causes.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 1 Deaths from all causes
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strang 2004a 16/70 21/73 28.3 % 0.79 [ 0.45, 1.39 ]
Strang 2004b 26/117 33/119 45.0 % 0.80 [ 0.51, 1.25 ]
Reuter 2006 0/7 0/18 Not estimable
Mayosi 2014 17/138 18/118 26.7 % 0.81 [ 0.44, 1.49 ]
Total (95% CI) 332 328 100.0 % 0.80 [ 0.59, 1.09 ]
Total events: 59 (Steroids), 72 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours steroids Favours placebo
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Analysis 1.2. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 2 Deaths from
pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 2 Deaths from pericarditis
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 3/138 6/118 25.7 % 0.43 [ 0.11, 1.67 ]
Reuter 2006 0/7 0/18 Not estimable
Strang 2004a 2/70 8/73 31.1 % 0.26 [ 0.06, 1.19 ]
Strang 2004b 5/117 11/119 43.3 % 0.46 [ 0.17, 1.29 ]
Total (95% CI) 332 328 100.0 % 0.39 [ 0.19, 0.80 ]
Total events: 10 (Steroids), 25 (Placebo)
Heterogeneity: Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours steroids Favours placebo
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Analysis 1.3. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 3 Constrictive
pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 3 Constrictive pericarditis
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 11/138 13/118 100.0 % 0.72 [ 0.34, 1.55 ]
Reuter 2006 0/7 0/18 Not estimable
Total (95% CI) 145 136 100.0 % 0.72 [ 0.34, 1.55 ]
Total events: 11 (Steroids), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours steroids Favours placebo
Analysis 1.4. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 4 Repeat
pericardiocentesis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 4 Repeat pericardiocentesis
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 82/138 71/118 77.0 % 0.99 [ 0.81, 1.21 ]
Strang 2004b 9/117 23/119 23.0 % 0.40 [ 0.19, 0.82 ]
Total (95% CI) 255 237 100.0 % 0.85 [ 0.70, 1.04 ]
Total events: 91 (Steroids), 94 (Placebo)
Heterogeneity: Chi2 = 6.27, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours steroids Favours placebo
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Analysis 1.5. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 5 Cancer.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 5 Cancer
Study or subgroup Steroids Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 1/138 1/118 100.0 % 0.85 [ 0.05, 13.80 ]
Total (95% CI) 138 118 100.0 % 0.85 [ 0.05, 13.80 ]
Total events: 1 (Steroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours steroids Favours placebo
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Analysis 1.6. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 6 Hospitalization.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 6 Hospitalization
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 23/138 20/118 100.0 % 0.98 [ 0.57, 1.70 ]
Total (95% CI) 138 118 100.0 % 0.98 [ 0.57, 1.70 ]
Total events: 23 (Steroids), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours steroids Favours placebo
Analysis 1.7. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 7 Pericardiectomy.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 7 Pericardiectomy
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Reuter 2006 0/7 0/18 Not estimable
Schrire 1959 4/14 0/14 1.5 % 9.00 [ 0.53, 152.93 ]
Strang 2004a 18/70 22/73 65.4 % 0.85 [ 0.50, 1.45 ]
Strang 2004b 7/117 11/119 33.1 % 0.65 [ 0.26, 1.61 ]
Total (95% CI) 208 224 100.0 % 0.91 [ 0.58, 1.41 ]
Total events: 29 (Steroids), 33 (Placebo)
Heterogeneity: Chi2 = 3.10, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours steroids Favours placebo
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Analysis 1.8. Comparison 1 Steroids versus placebo in HIV-negative people, Outcome 8 Opportunistic
infections.
Review: Interventions for treating tuberculous pericarditis
Comparison: 1 Steroids versus placebo in HIV-negative people
Outcome: 8 Opportunistic infections
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 6/138 3/118 100.0 % 1.71 [ 0.44, 6.69 ]
Total (95% CI) 138 118 100.0 % 1.71 [ 0.44, 6.69 ]
Total events: 6 (Steroids), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours steroids Favours placebo
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Analysis 2.1. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 1 Deaths from all
causes.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 1 Deaths from all causes
Study or subgroup Favours steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hakim 2000 5/29 10/29 40.6 % 0.50 [ 0.19, 1.28 ]
Reuter 2006 0/9 0/6 Not estimable
Mayosi 2014 50/242 39/260 59.4 % 1.38 [ 0.94, 2.01 ]
Total (95% CI) 280 295 100.0 % 0.91 [ 0.34, 2.42 ]
Total events: 55 (Favours steroids), 49 (Placebo)
Heterogeneity: Tau2 = 0.38; Chi2 = 3.82, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours steroids Favours placebo
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Analysis 2.2. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 2 Deaths from
pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 2 Deaths from pericarditis
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 10/242 10/260 100.0 % 1.07 [ 0.46, 2.54 ]
Reuter 2006 0/9 0/6 Not estimable
Total (95% CI) 251 266 100.0 % 1.07 [ 0.46, 2.54 ]
Total events: 10 (Steroids), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours steroids Favours placebo
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Analysis 2.3. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 3 Constrictive
pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 3 Constrictive pericarditis
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hakim 2000 2/29 2/29 10.5 % 1.00 [ 0.15, 6.63 ]
Mayosi 2014 7/242 17/260 86.4 % 0.44 [ 0.19, 1.05 ]
Reuter 2006 1/9 0/6 3.1 % 2.10 [ 0.10, 44.40 ]
Total (95% CI) 280 295 100.0 % 0.55 [ 0.26, 1.16 ]
Total events: 10 (Steroids), 19 (Placebo)
Heterogeneity: Chi2 = 1.37, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours steroids Favours placebo
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Analysis 2.4. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 4 Repeat
pericardiocentesis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 4 Repeat pericardiocentesis
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 151/242 158/260 99.2 % 1.03 [ 0.89, 1.18 ]
Reuter 2006 1/9 1/6 0.8 % 0.67 [ 0.05, 8.73 ]
Total (95% CI) 251 266 100.0 % 1.02 [ 0.89, 1.18 ]
Total events: 152 (Steroids), 159 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours steroids Favours placebo
Analysis 2.5. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 5 Cancer.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 5 Cancer
Study or subgroup Steroids Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 3/242 2/260 100.0 % 1.62 [ 0.27, 9.77 ]
Total (95% CI) 242 260 100.0 % 1.62 [ 0.27, 9.77 ]
Total events: 3 (Steroids), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours steroids Favours placebo
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Analysis 2.6. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 6 Hospitalization.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 6 Hospitalization
Study or subgroup Corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 53/242 71/260 100.0 % 0.80 [ 0.59, 1.09 ]
Total (95% CI) 242 260 100.0 % 0.80 [ 0.59, 1.09 ]
Total events: 53 (Corticosteroids), 71 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours corticosteroids Favours placebo
Analysis 2.7. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 7 Pericardiectomy.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 7 Pericardiectomy
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Reuter 2006 1/9 0/6 100.0 % 2.10 [ 0.10, 44.40 ]
Total (95% CI) 9 6 100.0 % 2.10 [ 0.10, 44.40 ]
Total events: 1 (Steroids), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours steroids Favours placebo
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Analysis 2.8. Comparison 2 Steroids versus placebo in HIV-positive people, Outcome 8 Opportunistic
infections.
Review: Interventions for treating tuberculous pericarditis
Comparison: 2 Steroids versus placebo in HIV-positive people
Outcome: 8 Opportunistic infections
Study or subgroup Steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 30/242 34/260 93.2 % 0.95 [ 0.60, 1.50 ]
Reuter 2006 3/9 2/6 6.8 % 1.00 [ 0.23, 4.31 ]
Total (95% CI) 251 266 100.0 % 0.95 [ 0.61, 1.48 ]
Total events: 33 (Steroids), 36 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours steroids Favours placebo
Analysis 3.1. Comparison 3 Colchicine versus placebo in HIV-positive people, Outcome 1 Death from all
causes.
Review: Interventions for treating tuberculous pericarditis
Comparison: 3 Colchicine versus placebo in HIV-positive people
Outcome: 1 Death from all causes
Study or subgroup Colchicine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liebenberg 2016 3/19 3/14 0.74 [ 0.17, 3.12 ]
0.1 0.2 0.5 1 2 5 10
Favours colchicine Favours placebo
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Analysis 3.2. Comparison 3 Colchicine versus placebo in HIV-positive people, Outcome 2 Constrictive
pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 3 Colchicine versus placebo in HIV-positive people
Outcome: 2 Constrictive pericarditis
Study or subgroup Colchicine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liebenberg 2016 3/19 2/14 1.11 [ 0.21, 5.76 ]
0.1 0.2 0.5 1 2 5 10
Favours colchicine Favours placebo
Analysis 4.1. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 1 Deaths
from all causes.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 1 Deaths from all causes
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 16/95 15/95 100.0 % 1.07 [ 0.56, 2.03 ]
Total (95% CI) 95 95 100.0 % 1.07 [ 0.56, 2.03 ]
Total events: 16 (M. indicus pranii), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 4.2. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 2 Deaths
from pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 2 Deaths from pericarditis
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 6/95 4/95 100.0 % 1.50 [ 0.44, 5.15 ]
Total (95% CI) 95 95 100.0 % 1.50 [ 0.44, 5.15 ]
Total events: 6 (M. indicus pranii), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours M. indicus pranii Favours placebo
Analysis 4.3. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 3
Constrictive pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 3 Constrictive pericarditis
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 14/95 9/95 100.0 % 1.56 [ 0.71, 3.42 ]
Total (95% CI) 95 95 100.0 % 1.56 [ 0.71, 3.42 ]
Total events: 14 (M. indicus pranii), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 4 Repeat
pericardiocentesis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 4 Repeat pericardiocentesis
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 64/95 53/95 100.0 % 1.21 [ 0.96, 1.52 ]
Total (95% CI) 95 95 100.0 % 1.21 [ 0.96, 1.52 ]
Total events: 64 (M. indicus pranii), 53 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Favours M. indicus pranii Favours placebo
Analysis 4.5. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 5 Cancer.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 5 Cancer
Study or subgroup Corticosteroids Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 1/95 0/95 100.0 % 3.03 [ 0.12, 75.37 ]
Total (95% CI) 95 95 100.0 % 3.03 [ 0.12, 75.37 ]
Total events: 1 (Corticosteroids), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 6
Hospitalization.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 6 Hospitalization
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 22/95 18/95 100.0 % 1.22 [ 0.70, 2.13 ]
Total (95% CI) 95 95 100.0 % 1.22 [ 0.70, 2.13 ]
Total events: 22 (M. indicus pranii), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours M. indicus pranii Favours placebo
Analysis 4.7. Comparison 4 M. indicus pranii versus placebo in HIV-negative people, Outcome 7
Opportunistic infections.
Review: Interventions for treating tuberculous pericarditis
Comparison: 4 M. indicus pranii versus placebo in HIV-negative people
Outcome: 7 Opportunistic infections
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 2/95 3/95 100.0 % 0.67 [ 0.11, 3.90 ]
Total (95% CI) 95 95 100.0 % 0.67 [ 0.11, 3.90 ]
Total events: 2 (M. indicus pranii), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 1 Deaths
from all causes.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 1 Deaths from all causes
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 36/205 35/209 100.0 % 1.05 [ 0.69, 1.60 ]
Total (95% CI) 205 209 100.0 % 1.05 [ 0.69, 1.60 ]
Total events: 36 (M. indicus pranii), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Favours M. indicus pranii Favours placebo
Analysis 5.2. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 2 Deaths
from pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 2 Deaths from pericarditis
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 4/205 8/209 100.0 % 0.51 [ 0.16, 1.67 ]
Total (95% CI) 205 209 100.0 % 0.51 [ 0.16, 1.67 ]
Total events: 4 (M. indicus pranii), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 3 Constrictive
pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 3 Constrictive pericarditis
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 10/205 14/209 100.0 % 0.73 [ 0.33, 1.60 ]
Total (95% CI) 205 209 100.0 % 0.73 [ 0.33, 1.60 ]
Total events: 10 (M. indicus pranii), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours M. indicus pranii Favours placebo
Analysis 5.4. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 4 Repeat
pericardiocentesis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 4 Repeat pericardiocentesis
Study or subgroup M. indicus pranii Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 116/205 126/209 100.0 % 0.94 [ 0.80, 1.10 ]
Total (95% CI) 205 209 100.0 % 0.94 [ 0.80, 1.10 ]
Total events: 116 (M. indicus pranii), 126 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 5 Cancer.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 5 Cancer
Study or subgroup M. indicus pranii Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 0/205 1/209 0.34 [ 0.01, 8.35 ]
0.01 0.1 1 10 100
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Analysis 5.6. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 6
Hospitalization.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 6 Hospitalization
Study or subgroup M. indicus pranii Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 59/205 55/209 1.09 [ 0.80, 1.50 ]
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Analysis 5.7. Comparison 5 M. indicus pranii versus placebo in HIV-positive people, Outcome 7
Opportunistic infections.
Review: Interventions for treating tuberculous pericarditis
Comparison: 5 M. indicus pranii versus placebo in HIV-positive people
Outcome: 7 Opportunistic infections
Study or subgroup M. indicus pranii Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayosi 2014 29/205 29/209 1.02 [ 0.63, 1.64 ]
0.5 0.7 1 1.5 2
Favours M. indicus pranii Favours placebo
Analysis 6.1. Comparison 6 Surgical drainage versus no intervention in HIV-negative people, Outcome 1
Death from all causes.
Review: Interventions for treating tuberculous pericarditis
Comparison: 6 Surgical drainage versus no intervention in HIV-negative people
Outcome: 1 Death from all causes
Study or subgroup Open drainage No open drainage Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strang 2004b 13/64 11/58 100.0 % 1.07 [ 0.52, 2.20 ]
Total (95% CI) 64 58 100.0 % 1.07 [ 0.52, 2.20 ]
Total events: 13 (Open drainage), 11 (No open drainage)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Surgical drainage versus no intervention in HIV-negative people, Outcome 2
Death from pericarditis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 6 Surgical drainage versus no intervention in HIV-negative people
Outcome: 2 Death from pericarditis
Study or subgroup Open drainage No open drainage Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strang 2004b 3/64 4/58 100.0 % 0.68 [ 0.16, 2.91 ]
Total (95% CI) 64 58 100.0 % 0.68 [ 0.16, 2.91 ]
Total events: 3 (Open drainage), 4 (No open drainage)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours open drainage Favours no open drainage
Analysis 6.3. Comparison 6 Surgical drainage versus no intervention in HIV-negative people, Outcome 3
Repeat pericardiocentesis.
Review: Interventions for treating tuberculous pericarditis
Comparison: 6 Surgical drainage versus no intervention in HIV-negative people
Outcome: 3 Repeat pericardiocentesis
Study or subgroup Open drainage No open drainage Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strang 2004b 3/64 12/58 100.0 % 0.23 [ 0.07, 0.76 ]
Total (95% CI) 64 58 100.0 % 0.23 [ 0.07, 0.76 ]
Total events: 3 (Open drainage), 12 (No open drainage)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Surgical drainage versus no intervention in HIV-negative people, Outcome 4
Pericardiectomy.
Review: Interventions for treating tuberculous pericarditis
Comparison: 6 Surgical drainage versus no intervention in HIV-negative people
Outcome: 4 Pericardiectomy
Study or subgroup Open drainage No open drainage Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strang 2004b 3/64 5/58 100.0 % 0.54 [ 0.14, 2.18 ]
Total (95% CI) 64 58 100.0 % 0.54 [ 0.14, 2.18 ]
Total events: 3 (Open drainage), 5 (No open drainage)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Favours open drainage Favours no open drainage
A D D I T I O N A L T A B L E S
Table 1. Key characteristics of the corticosteroid trials
Trial Location Participants Intervention Outcomes
Sample size Age (years) HIV-
positive
ART Definite TB
Schrire
1959
South Africa 28 people
with pericar-
dial effusion
Adults None N/A Not reported Cor-
tisone (or pred-
nisolone) for
several weeks
versus no corti-
costeroids1
Pericardiec-
tomy
Hakim
2000
Zimbabwe 58 people
with pericar-
dial effusion
18 to 55 100% 0% 38% Prednisolone
for 6 weeks ver-
sus placebo3
All-cause
deaths;
constrictive
pericarditis.
Strang
2004a
South Africa 143 with
constrictive
pericarditis
≥ 5 Assume
none
N/A 10% Prednisolone
first 11 weeks
versus placebo2
All-cause
deaths; deaths
from pericardi-
tis; pericardiec-
tomy.
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Table 1. Key characteristics of the corticosteroid trials (Continued)
Strang
2004b
South Africa 240 people
with pericar-
dial effusion
≥ 5 Assume
none
N/A 60% (1) Pred-
nisolone for
11 weeks versus
placebo
(2) Open surgi-
cal
drainage versus
no drainage
All-cause
deaths; deaths
from pericardi-
tis; repeat peri-
cardiocente-
sis; pericardiec-
tomy
Reuter 2006 South Africa 40 people
with pericar-
dial effusion
17 to 66 38% 0% Not reported Prednisone ver-
sus no pred-
nisone (5 mL
intrapericardial
0.9% saline)4
Repeat pericar-
diocente-
sis; pericardiec-
tomy; constric-
tive pericardi-
tis; infection
Mayosi
2014
Kenya,
Malawi,
Mozam-
bique, Nige-
ria, Uganda,
Sierra
Leone,
South
Africa, and
Zimbabwe
1440
with pericar-
dial effusion
(83%)
or constric-
tion (17%)
≥ 18 67% 22% 17% Pred-
nisolone for 6
weeks with or
without M. in-
dicus pranii ver-
sus placebo5
All-cause
deaths; deaths
from pericardi-
tis; constrictive
pericardi-
tis; hospitaliza-
tion; infection;
cancer
Abbreviations: ART: proportion of participants on antiretroviral therapy; HIV: human immunodeficiency virus; TB: tuberculosis.
1In the Schrire 1959 study, corticosteroid dose was given at a loading dose of 300 mg daily followed by a maintenance dose of 100 mg
daily. At a later date, cortisone was substituted by prednisolone with a loading dose of 60 mg daily and a maintenance dose of 20 mg
daily.
2In the Strang 2004a and Strang 2004b , the trial authors stratified prednisolone dosing by age: The dose for children aged 5 to 9 years
was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. For
children 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week
11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 11.
3In the Hakim 2000 study, the dose of prednisolone was 60 mg daily for the first week and was tapered thereafter by 10 mg every week.
4In the Reuter 2006 study, the corticosteroid arm received oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution).
Oral prednisone was started at 60 mg per day for 4 weeks, followed by 30 mg per day for 4 weeks, 15 mg per day for 2 weeks, and 5
mg per day for 1 week. This study had 3 arms. We did not include the third trial arm, which received intrapericardial triamcinolone,
in this current review.
5Mayosi 2014 used prednisolone for six weeks at a dose of 120 mg per day in the first week, 90 mg per day in the second week, 60 mg
per day in the third week, 30 mg per day in the fourth week, 15 mg per day in the fifth week, and 5 mg per day in the sixth week.
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A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set CIDG SR1 CENTRAL MEDLINE2 Embase2 LILACS2
1 tuberculosis Tuberculosis [MeSH] Tuberculosis [MeSH] Tuberculosis [MeSH] tuberculosis
2 Pericard* Tuberculosis ti, ab Tuberculosis ti, ab Tuberculosis ti, ab Pericard*
3 heart 1 or 2 1 or 2 1 or 2 heart
4 2 or 3 heart or cardi* or peri-
card* ti, ab
heart or cardi* or peri-
card* ti, ab
heart or cardi* or peri-
card* ti, ab
2 or 3
5 1 and 4 3 and 4 3 and 4 3 and 4 1 and 4
6 - “Pericarditis, Tubercu-
lous”[Mesh]
“Pericarditis, Tubercu-
lous”[Mesh]
tuberculous pericarditis
[Emtree]
-
7 - 5 or 6 5 or 6 5 or 6 -
1Cochrane Infectious Diseases Group Specialized Register.
2Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration (Lefebvre
2011).
WH A T ’ S N E W
Last assessed as up-to-date: 27 March 2017.
Date Event Description
12 September 2017 New citation required and conclusions have changed We updated this review, added new authors, and
included new trials. The conclusion of this review
changed compared to the previous published version
12 September 2017 New search has been performed The author team updated this review.
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H I S T O R Y
Protocol first published: Issue 4, 1997
Review first published: Issue 3, 1998
Date Event Description
10 November 2008 Amended Converted to new review format with minor editing.
12 January 2005 Amended New studies found but not yet included or excluded.
18 May 2003 Amended Minor update
17 June 2002 New citation required and conclusions have changed Substantive amendment. Issue 4, 2002: Hakim 2000
added.
New studies found and included or excluded
C O N T R I B U T I O N S O F A U T H O R S
Charles S Wiysonge and Bongani MMayosi led the preparation of the current version of the review, with important intellectual inputs
from all co-authors.
Charles S Wiysonge and Bongani M Mayosi were involved in all stages of the review.
Dumisani Majombozi was involved in screening of searches, study selection, data extraction, and verification of data analysis.
Freedom Gumedze provided the data on the Mayosi 2014 trial and verified the data analysis.
Mpiko Ntsekhe, Lehana Thabane, Jimmy Volmink, and Shaheen Pandie read and provided important input into successive drafts of
the review.
All review authors read and approved the final version of the review.
D E C L A R A T I O N S O F I N T E R E S T
Mpiko Ntsekhe, Lehana Thabane, Freedom Gumedze, Shaheen Pandie, and Bongani M Mayosi were investigators in an included
study (Mayosi 2014). Jimmy Volmink was a member of the Data Safety and Monitoring Committee for the same study. However, two
review authors (CSW and DM) who were not involved in this trial independently extracted the data for this study, which were verified
by Paul Garner, David Sinclair, Hannah Ryan, and Maya Tickell-Painter.
Charles S Wiysonge, Mpiko Ntsekhe, Jimmy Volmink, and Bongani MMayosi were co-authors of a study assessed and excluded from
the review (Wiysonge 2008). A review author (DM) who was not involved in this study initially assessed the eligibility of this study.
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S O U R C E S O F S U P P O R T
Internal sources
• Cardiac Clinic Research Fund, University of Cape Town, South Africa.
• Stellenbosch University, South Africa.
• South African Medical Research Council, South Africa.
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Grant: 5242
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are differences between the authors of the protocol and the current version of the review. The protocol had three authors (Bongani
Mayosi, Jimmy Volmink, and Patrick Commerford), while this review update has eight review authors.
The protocol set out to assess the effects of only four interventions (six-month antituberculous drug regimens compared with regimens
of nine months or more, corticosteroids, pericardial drainage, and pericardiectomy). However, in this review we have assessed the effects
of any intervention used to treat tuberculous pericarditis.
The protocol did not report cancer as a potential outcome, but we have reported outcome data on cancer in this version of the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [therapeutic use]; Antitubercular Agents [therapeutic use]; Cause of Death; Colchicine [therapeutic use];
Drainage; HIV Seronegativity; HIV Seropositivity [drug therapy]; Immunotherapy; Pericardiectomy; Pericarditis, Tuberculous [com-
plications; ∗drug therapy; mortality; ∗surgery]; Pericardium [surgery]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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